{
  "url": "https://openlegislation.uk/eu-regulation-2009-790/annex-II",
  "json_url": "https://openlegislation.uk/eu-regulation-2009-790/annex-II.json",
  "legislation": "eur/2009/790",
  "legislation_title": "Commission Regulation (EC) No 790/2009 of 10 August 2009 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2009-790",
  "path": "annex/II",
  "kind": "annex",
  "number": "II",
  "heading": null,
  "text": "Index No\nInternational Chemical Identification\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits M-factors\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n003-003-00-5\n(2-methylpropyl)lithium;\nisobutyllithium\n440-620-2\n920-36-5\nWater-react. 1\nPyr. Liq. 1\nSkin Corr. 1A\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH260\nH250\nH314\nH336\nH400\nH410\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH260\nH250\nH314\nH336\nH410\nEUH014\n005-007-00-2\nboric acid; [1]\nboric acid, crude natural, containing not more than 85 per cent of H3BO3 calculated on the dry weight [2]\n233-139-2 [1]\n234-343-4 [2]\n10043-35-3 [1]\n11113-50-1 [2]\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥ 5,5 %\n005-008-00-8\ndiboron trioxide;\nboric oxide\n215-125-8\n1303-86-2\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥ 3,1 %\n005-011-00-4\ndisodium tetraborate, anhydrous;\nboric acid, disodium salt; [1]\ntetraboron disodium heptaoxide, hydrate; [2]\northoboric acid, sodium salt [3]\n215-540-4 [1]\n235-541-3 [2]\n237-560-2 [3]\n1330-43-4 [1]\n12267-73-1 [2]\n13840-56-7 [3]\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥ 4,5 %\n005-011-01-1\ndisodium tetraborate decahydrate;\nborax decahydrate\n215-540-4\n1303-96-4\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥ 8,5 %\n005-011-02-9\ndisodium tetraborate pentahydrate;\nborax pentahydrate\n215-540-4\n12179-04-3\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD\nRepr. 1B; H360FD: C ≥ 6,5 %\n005-013-00-5\ndiethylmethoxyborane\n425-380-9\n7397-46-8\nPyr. Liq. 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 4\nH250\nH332\nH312\nH302\nH373**\nH314\nH317\nH413\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH250\nH332\nH312\nH302\nH373**\nH314\nH317\nH413\n005-014-00-0\n4-formylphenylboronic acid\n438-670-5\n87199-17-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n005-015-00-6\n1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)\n414-380-4\n140681-55-6\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n005-016-00-1\ntetrabutylammonium butyl tris-(4-tert-butylphenyl)borate\n431-370-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n005-017-00-7\nsodium perborate; [1]\nsodium peroxometaborate; [2]\nsodium peroxoborate;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n231-556-4 [2]\n15120-21-5 [1]\n7632-04-4 [2]\nOxid. Sol. 2\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH302\nH335\nH318\nGHS03\nGHS05\nGHS08\nGHS07\nDgr\nH272\nH360Df\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥ 9 %\nRepr. 1B; H360D: 6,5 % ≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-017-01-4\nsodium perborate; [1]\nsodium peroxometaborate; [2]\nsodium peroxoborate;\n[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n231-556-4 [2]\n15120-21-5 [1]\n7632-04-4 [2]\nOxid. Sol. 2\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH331\nH302\nH335\nH318\nGHS03\nGHS06\nGHS05\nGHS08\nDgr\nH272\nH360Df\nH331\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥ 9 %\nRepr. 1B; H360D: 6,5 % ≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-018-00-2\nperboric acid (H3BO2(O2)), monosodium salt trihydrate; [1]\nperboric acid, sodium salt, tetrahydrate; [2]\nperboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]\nsodium peroxoborate hexahydrate;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n234-390-0 [2]\n231-556-4 [3]\n13517-20-9 [1]\n37244-98-7 [2]\n10486-00-7 [3]\nRepr. 1B\nSTOT SE 3\nEye Dam. 1\nH360Df\nH335\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH360Df\nH335\nH318\nRepr. 1B; H360 Df: C ≥ 14 %\nRepr. 1B; H360D: 10 % ≤ C < 14 %\nEye Dam. 1; H318: C ≥ 36 %\nEye Irrit. 2; H319: 22 % ≤ C < 36 %\n005-018-01-X\nperboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1]\nperboric acid, sodium salt, tetrahydrate; [2]\nperboric acid (HBO(O2)), sodium salt, tetrahydrate; [3]\nsodium peroxoborate hexahydrate;\n[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n239-172-9 [1]\n234-390-0 [2]\n231-556-4 [3]\n13517-20-9 [1]\n37244-98-7 [2]\n10486-00-7 [3]\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH360Df\nH332\nH335\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH360Df\nH332\nH335\nH318\nRepr. 1B; H360 Df: C ≥ 14 %\nRepr. 1B; H360D: 10 % ≤ C < 14 %\nEye Dam. 1; H318: C ≥ 36 %\nEye Irrit. 2; H319: 22 % ≤ C < 36 %\n005-019-00-8\nperboric acid, sodium salt; [1]\nperboric acid, sodium salt, monohydrate; [2]\nperboric acid (HBO(O2)), sodium salt, monohydrate; [3]\nsodium peroxoborate;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n234-390-0 [1]\n234-390-0 [2]\n231-556-4 [3]\n11138-47-9 [1]\n12040-72-1 [2]\n10332-33-9 [3]\nOxid. Sol. 3\nRepr. 1B\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH302\nH335\nH318\nGHS03\nGHS05\nGHS08\nGHS07\nDgr\nH272\nH360Df\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥ 9 %\nRepr. 1B; H360D: 6,5 % ≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n005-019-01-5\nperboric acid, sodium salt; [1]\nperboric acid, sodium salt, monohydrate; [2]\nperboric acid (HBO(O2)), sodium salt, monohydrate; [3]\nsodium peroxoborate;\n[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n234-390-0 [1]\n234-390-0 [2]\n231-556-4 [3]\n11138-47-9 [1]\n12040-72-1 [2]\n10332-33-9 [3]\nOxid. Sol. 3\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT SE 3\nEye Dam. 1\nH272\nH360Df\nH331\nH302\nH335\nH318\nGHS03\nGHS06\nGHS05\nGHS08\nDgr\nH272\nH360Df\nH331\nH302\nH335\nH318\nRepr. 1B; H360Df: C ≥ 9 %\nRepr. 1B; H360D: 6,5 % ≤ C < 9 %\nEye Dam. 1; H318: C ≥ 22 %\nEye Irrit. 2; H319: 14 % ≤ C < 22 %\n006-091-00-3\npropineb (ISO);\npolymeric zinc propylenebis(dithiocarbamate)\n—\n9016-72-2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nH332\nH373**\nH317\nH400\nGHS08\nGHS07\nGHS09\nWng\nH332\nH373**\nH317\nH400\n006-092-00-9\ntert-butyl (1S)-N-[1-((2S)-2-oxiranyl)-2-phenylethyl]carbamate\n425-420-5\n98737-29-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n006-093-00-4\n2,2'-dithio di(ethylammonium)-bis(dibenzyldithiocarbamate)\n427-180-7\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n006-094-00-X\nO-isobutyl-N-ethoxy carbonylthiocarbamate\n434-350-4\n103122-66-3\nFlam. Liq. 3\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH226\nH350\nH340\nH302\nH373**\nH317\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH350\nH340\nH302\nH373**\nH317\nH411\n006-095-00-5\nfosetyl-aluminium (ISO);\naluminium triethyl triphosphonate\n254-320-2\n39148-24-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n006-096-00-0\nchlorpropham (ISO);\nisopropyl 3-chlorocarbanilate\n202-925-7\n101-21-3\nCarc. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH351\nH373**\nH411\nGHS08\nGHS09\nWng\nH351\nH373**\nH411\n006-097-00-6\n1-phenyl-3-(p-toluenesulfonyl)urea\n424-620-1\n13909-63-2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n006-098-00-1\ntert-butyl (1R, 5S)-3-azabicyclo[3.1.0]hex-6-ylcarbamate\n429-170-8\n134575-17-0\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgrg\nH302\nH373**\nH318\nH317\n006-099-00-7\nN-(p-toluenesulfonyl)-N'-(3-(p-toluenesulfonyloxy)phenyl)urea;\n3-({][}(4-methylphenyl)sulfonyl{]carbamoyl[}amino)phenyl 4-methylbenzenesulfonate\n520-2\n232938-43-1\nAquatic Chronic 2\nH411\nGHS09\nH411\n006-101-00-6\nreaction mass of: N,N''-(methylenedi-4,1-phenylene)bis[N'-phenylurea];\nN-(4-[[4-[[(phenylamino)carbonyl]amino]phenylmethyl]phenyl]-N'-cyclohexylurea;\nN,N''-(methylenedi-4,1-phenylene)bis[N'-cyclohexylurea]\n423-070-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n006-102-00-1\nO-hexyl-N-ethoxycarbonylthiocarbamate\n432-750-3\n—\nCarc. 1B\nMuta. 1B\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH350\nH340\nH302\nH373**\nH317\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH340\nH302\nH373**\nH317\nH411\n006-103-00-7\nN,N''-(methylenedi-4,1-phenylene)bis[N'-octyl]urea\n445-760-8\n—\nEye Dam. 1\nResp. Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH334\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH318\nH334\nH410\nM=100\n007-028-00-2\nhydroxylammonium nitrate\n236-691-2\n13465-08-2\nExpl. 1.1 ****\nCarc. 2\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH201\nH351\nH311\nH302\nH373**\nH319\nH315\nH317\nH400\nGHS01\nGHS06\nGHS08\nGHS09\nDgr\nH201\nH351\nH311\nH302\nH373**\nH319\nH315\nH317\nH400\n007-029-00-8\ndiethyldimethylammonium hydroxide\n419-400-5\n95500-19-9\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1A\nH312\nH302\nH314\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\n012-004-00-X\naluminium-magnesium-carbonate-hydroxide-perchlorate-hydrate\n422-150-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n013-010-00-5\nhydroxy aluminium bis(2,4,8,10-tetra-tert-butyl-6-hydroxy-12H-dibenzo[d,g][1.3.2]dioxaphosphocin-6-oxide)\n430-650-4\n151841-65-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-033-00-3\n2-methyl-3-(trimethoxysilyl)propyl-2-propenoate hydrolysis product with silica\n419-030-4\n125804-20-8\nFlam. Liq. 2\nEye Irrit. 2\nSTOT SE 3\nH225\nH319\nH336\nGHS02\nGHS07\nDgr\nH225\nH319\nH336\n014-034-00-9\n3-hexylheptamethyltrisiloxane\n428-700-5\n1873-90-1\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n014-035-00-4\n2-(3,4-epoxycyclohexyl)ethyltriethoxy silane\n425-050-4\n10217-34-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n014-036-00-X\n(4-ethoxyphenyl)(3-(4-fluoro-3-phenoxyphenyl)propyl)dimethylsilane\n405-020-7\n105024-66-6\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360F***\nH400\nH410\nGHS08\nGHS09\nDgr\nH360F***\nH410\nM=1000\n014-037-00-5\n2-butanone-O,O',O''-(phenylsilylidyne)trioxime\n433-360-6\n34036-80-1\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373**\nH317\nH412\nGHS08\nGHS07\nWng\nH373**\nH317\nH412\n014-038-00-0\nS-(3-(triethoxysilyl)propyl) octanethioate\n436-690-9\n220727-26-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n014-039-00-6\n(2,3-dimethylbut-2-yl)-trimethoxysilane\n439-360-2\n142877-45-0\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n014-041-00-7\nN,N-bis(trimethylsilyl)aminopropylmethyldiethoxysilane\n445-890-5\n201290-01-9\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n014-042-00-2\nreaction mass of: O,O',O'',O'''-silanetetrayl tetrakis(4-methyl-2-pentanone oxime) (3 stereoisomers)\n423-010-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n014-043-00-8\nreaction product of amorphous silica (50-85 %), butyl (1-methylpropyl) magnesium (3-15 %), tetraethyl orthosilicate (5-15 %) and titanium tetrachloride (5-20 %)\n432-200-2\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-044-00-3\n3-[(4'-acetoxy-3'-methoxyphenyl) propyl]trimethoxysilane\n433-050-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n014-045-00-9\nmagnesium sodium fluoride silicate\n442-650-1\n—\nSTOT RE 2 *\nH373**\nGHS08\nWng\nH373**\n015-113-00-0\ntolclofos-methyl (ISO);\nO-(2,6-dichloro-p-tolyl)-O,O-dimethyl thiophosphate\n260-515-3\n57018-04-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n015-182-00-7\ntetraisopropyldichloromethylenebisphosphonate\n430-630-5\n10596-22-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS06\nWng\nH302\nH319\nH317\n015-183-00-2\n(1-hydroxydodecylidene)diphosphonic acid\n425-230-2\n16610-63-2\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n015-188-00-X\n(1-methylethylidene)di-4,1-phenylenetetraphenyl diphosphate\n425-220-8\n5945-33-5\nAquatic Chronic 4\nH413\n—\nH413\n015-190-00-0\nbis(2,4-dicumylphenyl) neopentyl diphosphite;\n3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane\n421-920-2\n154862-43-8\nAquatic Chronic 4\nH413\n—\nH413\n015-191-00-6\ndodecyldiphenyl phosphate\n431-760-5\n27460-02-2\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n015-192-00-1\ntetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate\n432-770-2\n139189-30-3\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n015-193-00-7\ntriphenyl(phenylmethyl)phosphonium 1,1,2,2,3,3,4,4,4-nonafluoro-N-methyl-1-butanesulfonamide (1:1)\n442-960-7\n332350-93-3\nAcute Tox. 3 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH400\nH410\nGHS05\nGHS06\nGHS09\nDgr\nH301\nH318\nH410\n015-194-00-2\ntetrabutyl-phosphonium nonafluoro-butane-1-sulfonate\n444-440-5\n220689-12-3\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n015-195-00-8\nreaction mass of: potassium o-toluenephosphonate;\npotassium m-toluenephosphonate;\npotassium p-toluenephosphonate\n433-860-4\n—\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH319\nH317\nH412\nGHS07\nWng\nH319\nH317\nH412\n015-196-00-3\nreaction mass of: dimethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate;\ndiethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate;\nmethyl ethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate\n435-960-3\n—\nCarc. 1B\nMuta. 1B\nSkin Sens. 1\nH350\nH340\nH317\nGHS08\nGHS07\nDgr\nH350\nH340\nH317\n015-197-00-9\nbis(2,4,4-trimethylpentyl)dithiophosphonic acid\n420-160-9\n107667-02-7\nFlam. Liq. 3\nAcute Tox. 3 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH226\nH331\nH302\nH314\nH411\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH226\nH331\nH302\nH314\nH411\n015-198-00-4\n(4-phenylbutyl)phosphinic acid\n420-450-5\n86552-32-1\nCarc. 2\nEye Dam. 1\nH351\nH318\nGHS05\nGHS08\nDgr\nH351\nH318\n016-092-00-0\nreaction mass of: 4,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol;\n4,8-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol;\n5,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol\n427-050-1\n—\nRepr. 1A\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f\nH315\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH361f\nH315\nH317\nH410\n016-094-00-1\nsulfur\n231-722-6\n7704-34-9\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n016-097-00-8\n1-amino-2-methyl-2-propanethiol hydrochloride\n434-480-1\n32047-53-3\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\nH412\n017-023-00-7\n[phosphinyldynetris(oxy)] tris[3-aminopropyl-2-hydroxy-N,N-dimethyl-N-(C6-18)-alkyl] trichlorides\n425-520-9\n197179-61-6\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n022-004-00-1\npotassium titanium oxide (K2Ti6O13)\n432-240-0\n12056-51-8\nCarc. 2\nH351\nGHS08\nDgr\nH351\n022-005-00-7\n[N-(1,1-dimethylethyl)-1,1-dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN][(1,2,3,4-η)-1,3-pentadiene]-titanium\n419-840-8\n169104-71-6\nFlam. Sol. 1****\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 4\nH228\nH314\nH317\nH413\nGHS02\nGHS05\nGHS07\nDgr\nH228\nH314\nH317\nH413\n024-021-00-X\npotassium tetrasodium bis[(N,N'-n)-1'-(phenylcarbamoyl)-3,5-disulfonatobenzeneazo-1'-prop-1'-ene-2,2'-diolato]chromate(III)\n425-830-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n026-003-00-7\niron (II) sulfate\n231-753-5\n7720-78-7\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\n026-003-01-4\niron (II) sulfate (1:1) heptahydrate;\nsulfuric acid, iron(II) salt (1:1), heptahydrate;\nferrous sulfate heptahydrate\n231-753-5\n7782-63-0\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nH302\nH319\nH315\nGHS07\nWng\nH302\nH319\nH315\nSkin Irrit. 2; H315: C ≥ 25 %\n026-004-00-2\npotassium ferrite\n430-010-4\n12160-44-0\nSkin Corr. 1B\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n027-006-00-6\ncobalt acetate\n200-755-8\n71-48-7\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F***\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F***\nH334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 %\nM=10\n1\n027-007-00-1\nzinc hexacyanocobaltate(III), tertiary butyl alcohol/polypropylene glycol complex\n425-240-7\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n027-008-00-7\ncomplex of cobalt(III)-bis(N-phenyl-4-(5-ethylsulfonyl-2-hydroxyphenylazo)-3-hydroxynaphthylamide), hydrated (n H2O,2<n<3)\n427-390-9\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n027-009-00-2\ncobalt nitrate\n233-402-1\n10141-05-6\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F***\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F***\nH334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 %\nM=10\n1\n027-010-00-8\ncobalt carbonate\n208-169-4\n513-79-1\nCarc. 1B\nMuta. 2\nRepr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360F***\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360F***\nH334\nH317\nH410\nCarc. 1B; H350i: C ≥ 0,01 %\nM=10\n1\n028-002-01-4\nnickel powder;\n[particle diameter < 1 mm]\n231-111-4\n7440-02-0\nCarc. 2\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 3\nH351\nH372**\nH317\nH412\nGHS08\nGHS07\nDgr\nH351\nH372**\nH317\nH412\n028-011-00-6\nnickel dichloride\n231-743-0\n7718-54-9\nCarc. 1A\nMuta. 2\nRepr. 1B\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH331\nH301\nH372**\nH315\nH334\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH331\nH301\nH372**\nH315\nH334\nH317\nH410\nSTOT RE. 1; H373: C ≥ 1 %\nSTOT RE. 2; H373: 0,1 % < C < 1 %\nSkin Irrit. 2; H315: C ≥ 20 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-012-00-1\nnickel dinitrate; [1]\nnitric acid, nickel salt [2]\n236-068-5 [1]\n238-076-4 [2]\n13138-45-9 [1]\n14216-75-2 [2]\nOx. Sol. 2\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH272\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH318\nH315\nH317\nH400\nH410\nGHS03\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH272\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH318\nH315\nH317\nH410\nSTOT RE. 1; H373: C ≥ 1 %\nSTOT RE. 2; H373: 0,1 % < C < 1 %\nSkin Irrit. 2; H315: C ≥ 20 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-013-00-7\nnickel matte\n273-749-6\n69012-50-6\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-014-00-2\nslimes and sludges, copper electrolytic refining, decopperised, nickel sulfate\n295-859-3\n92129-57-2\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH315\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH315\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-015-00-8\nslimes and sludges, copper electrolyte refining, decopperised\n305-433-1\n94551-87-8\nCarc. 1A\nMuta. 2\nRepr. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nH\n028-016-00-3\nnickel diperchlorate;\nperchloric acid, nickel(II) salt\n237-124-1\n13637-71-3\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH314\nH334\nH317\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH314\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-017-00-9\nnickel dipotassium bis(sulfate); [1]\ndiammonium nickel bis(sulfate) [2]\n237-563-9 [1]\n239-793-2 [2]\n13842-46-1 [1]\n15699-18-0 [2]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-018-00-4\nnickel bis(sulfamidate);\nnickel sulfamate\n237-396-1\n13770-89-3\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-019-00-X\nnickel bis(tetrafluoroborate)\n238-753-4\n14708-14-6\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-021-00-0\nnickel diformate; [1]\nformic acid, nickel salt; [2]\nformic acid, copper nickel salt [3]\n222-101-0 [1]\n239-946-6 [2]\n268-755-0 [3]\n3349-06-2 [1]\n15843-02-4 [2]\n68134-59-8 [3]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-022-00-6\nnickel di(acetate); [1]\nnickel acetate [2]\n206-761-7 [1]\n239-086-1 [2]\n373-02-4 [1]\n14998-37-9 [2]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH334\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH332\nH302\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nE H\n028-024-00-7\nnickel dibenzoate\n209-046-8\n553-71-9\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-025-00-2\nnickel bis(4-cyclohexylbutyrate)\n223-463-2\n3906-55-6\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\n028-026-00-8\nnickel(II) stearate;\nnickel(II) octadecanoate\n218-744-1\n2223-95-2\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-027-00-3\nnickel dilactate\n—\n16039-61-5\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-028-00-9\nnickel(II) octanoate\n225-656-7\n4995-91-9\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH314\nH334\nH317\nH400\nH410\nGHS05\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH314\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-029-00-4\nnickel difluoride; [1]\nnickel dibromide; [2]\nnickel diiodide; [3]\nnickel potassium fluoride [4]\n233-071-3 [1]\n236-665-0 [2]\n236-666-6 [3]\n- [4]\n10028-18-9 [1]\n13462-88-9 [2]\n13462-90-3 [3]\n11132-10-8 [4]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-030-00-X\nnickel hexafluorosilicate\n247-430-7\n26043-11-8\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-031-00-5\nnickel selenate\n239-125-2\n15060-62-5\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-032-00-0\nnickel hydrogen phosphate; [1]\nnickel bis(dihydrogen phosphate); [2]\ntrinickel bis(orthophosphate); [3]\ndinickel diphosphate; [4]\nnickel bis(phosphinate); [5]\nnickel phosphinate; [6]\nphosphoric acid, calcium nickel salt; [7]\ndiphosphoric acid, nickel(II) salt [8]\n238-278-2 [1]\n242-522-3 [2]\n233-844-5 [3]\n238-426-6 [4]\n238-511-8 [5]\n252-840-4 [6]\n- [7]\n- [8]\n14332-34-4 [1]\n18718-11-1 [2]\n10381-36-9 [3]\n14448-18-1 [4]\n14507-36-9 [5]\n36026-88-7 [6]\n17169-61-8 [7]\n19372-20-4 [8]\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nH\n028-033-00-6\ndiammonium nickel hexacyanoferrate\n—\n74195-78-1\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nH\n028-034-00-1\nnickel dicyanide\n209-160-8\n557-19-7\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nEUH032\nH\n028-035-00-7\nnickel chromate\n238-766-5\n14721-18-7\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nH\n028-036-00-2\nnickel(II) silicate; [1]\ndinickel orthosilicate; [2]\nnickel silicate (3:4); [3]\nsilicic acid, nickel salt; [4]\ntrihydrogen hydroxybis[orthosilicato(4-)]trinickelate(3-) [5]\n244-578-4 [1]\n237-411-1 [2]\n250-788-7 [3]\n253-461-7 [4]\n235-688-3 [5]\n21784-78-1 [1]\n13775-54-7 [2]\n31748-25-1 [3]\n37321-15-6 [4]\n12519-85-6 [5]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-037-00-8\ndinickel hexacyanoferrate\n238-946-3\n14874-78-3\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-038-00-3\ntrinickel bis(arsenate);\nnickel(II) arsenate\n236-771-7\n13477-70-8\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH372**\nH317\nH410\nH\n028-039-00-9\nnickel oxalate; [1]\noxalic acid, nickel salt [2]\n208-933-7 [1]\n243-867-2 [2]\n547-67-1 [1]\n20543-06-0 [2]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-040-00-4\nnickel telluride\n235-260-6\n12142-88-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-041-00-X\ntrinickel tetrasulfide\n—\n12137-12-1\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-042-00-5\ntrinickel bis(arsenite)\n—\n74646-29-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-043-00-0\ncobalt nickel gray periclase;\nC.I. Pigment Black 25;\nC.I. 77332; [1]\ncobalt nickel dioxide; [2]\ncobalt nickel oxide [3]\n269-051-6 [1]\n261-346-8 [2]\n- [3]\n68186-89-0 [1]\n58591-45-0 [2]\n12737-30-3 [3]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH\n028-044-00-6\nnickel tin trioxide;\nnickel stannate\n234-824-9\n12035-38-0\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH\n028-045-00-1\nnickel triuranium decaoxide\n239-876-6\n15780-33-3\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH\n028-046-00-7\nnickel dithiocyanate\n237-205-1\n13689-92-4\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nEUH032\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-047-00-2\nnickel dichromate\n239-646-5\n15586-38-6\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-048-00-8\nnickel(II) selenite\n233-263-7\n10101-96-9\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nH\n028-049-00-3\nnickel selenide\n215-216-2\n1314-05-2\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-050-00-9\nsilicic acid, lead nickel salt\n—\n68130-19-8\nCarc. 1A\nRepr. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH360Df\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH360Df\nH372**\nH317\nH410\nH\n028-051-00-4\nnickel diarsenide; [1]\nnickel arsenide [2]\n235-103-1 [1]\n248-169-1 [2]\n12068-61-0 [1]\n27016-75-7 [2]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-052-00-X\nnickel barium titanium primrose priderite;\nC.I. Pigment Yellow 157;\nC.I. 77900\n271-853-6\n68610-24-2\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH\n028-053-00-5\nnickel dichlorate; [1]\nnickel dibromate; [2]\nethyl hydrogen sulfate, nickel(II) salt [3]\n267-897-0 [1]\n238-596-1 [2]\n275-897-7 [3]\n67952-43-6 [1]\n14550-87-9 [2]\n71720-48-4 [3]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %1\nM=1\nH\n028-054-00-0\nnickel(II) trifluoroacetate; [1]\nnickel(II) propionate; [2]\nnickel bis(benzenesulfonate); [3]\nnickel(II) hydrogen citrate; [4]\ncitric acid, ammonium nickel salt; [5]\ncitric acid, nickel salt; [6]\nnickel bis(2-ethylhexanoate); [7]\n2-ethylhexanoic acid, nickel salt; [8]\ndimethylhexanoic acid nickel salt; [9]\nnickel(II) isooctanoate; [10]\nnickel isooctanoate; [11]\nnickel bis(isononanoate); [12]\nnickel(II) neononanoate; [13]\nnickel(II) isodecanoate; [14]\nnickel(II) neodecanoate; [15]\nneodecanoic acid, nickel salt; [16]\nnickel(II) neoundecanoate; [17]\nbis(d-gluconato-O 1,O 2)nickel; [18]\nnickel 3,5-bis(tert-butyl)-4-hydroxybenzoate (1:2); [19]\nnickel(II) palmitate; [20]\n(2-ethylhexanoato-O)(isononanoato-O)nickel; [21]\n(isononanoato-O)(isooctanoato-O)nickel; [22]\n(isooctanoato-O)(neodecanoato-O)nickel; [23]\n(2-ethylhexanoato-O)(isodecanoato-O)nickel; [24]\n(2-ethylhexanoato-O)(neodecanoato-O)nickel; [25]\n(isodecanoato-O)(isooctanoato-O)nickel; [26]\n(isodecanoato-O)(isononanoato-O)nickel; [27]\n(isononanoato-O)(neodecanoato-O)nickel; [28]\nfatty acids, C6-19-branched, nickel salts; [29]\nfatty acids, C8-18 and C18-unsaturated, nickel salts; [30]\n2,7-naphthalenedisulfonic acid, nickel(II) salt; [31]\n240-235-8 [1]\n222-102-6 [2]\n254-642-3 [3]\n242-533-3 [4]\n242-161-1 [5]\n245-119-0 [6]\n224-699-9 [7]\n231-480-1 [8]\n301-323-2 [9]\n249-555-2 [10]\n248-585-3 [11]\n284-349-6 [12]\n300-094-6 [13]\n287-468-1 [14]\n287-469-7 [15]\n257-447-1 [16]\n300-093-0 [17]\n276-205-6 [18]\n258-051-1 [19]\n237-138-8 [20]\n287-470-2 [21]\n287-471-8 [22]\n284-347-5 [23]\n284-351-7 [24]\n285-698-7 [25]\n285-909-2 [26]\n284-348-0 [27]\n287-592-6 [28]\n294-302-1 [29]\n283-972-0 [30]\n- [31]\n16083-14-0 [1]\n3349-08-4 [2]\n39819-65-3 [3]\n18721-51-2 [4]\n18283-82-4 [5]\n22605-92-1 [6]\n4454-16-4 [7]\n7580-31-6 [8]\n93983-68-7 [9]\n29317-63-3 [10]\n27637-46-3 [11]\n84852-37-9 [12]\n93920-10-6 [13]\n85508-43-6 [14]\n85508-44-7 [15]\n51818-56-5 [16]\n93920-09-3 [17]\n71957-07-8 [18]\n52625-25-9 [19]\n13654-40-5 [20]\n85508-45-8 [21]\n85508-46-9 [22]\n84852-35-7 [23]\n84852-39-1 [24]\n85135-77-9 [25]\n85166-19-4 [26]\n84852-36-8 [27]\n85551-28-6 [28]\n91697-41-5 [29]\n84776-45-4 [30]\n72319-19-8 [31]\nCarc. 1A\nMuta. 2\nRepr. 1B\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH341\nH360D***\nH372**\nH334\nH317\nH410\nSTOT RE 1; H372: C ≥ 1 %\nSTOT RE 2; H373: 0,1 % ≤ C < 1 %\nSkin Sens. 1; H317: C ≥ 0,01 %\nM=1\nH\n028-055-00-6\nnickel(II) sulfite; [1]\nnickel tellurium trioxide; [2]\nnickel tellurium tetraoxide; [3]\nmolybdenum nickel hydroxide oxide phosphate [4]\n231-827-7 [1]\n239-967-0 [2]\n239-974-9 [3]\n268-585-7 [4]\n7757-95-1 [1]\n15851-52-2 [2]\n15852-21-8 [3]\n68130-36-9 [4]\nCarc. 1A\nSTOT RE 1\nResp. Sens. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH334\nH317\nH400\nH410\nGHS08\nGHS09\nDgr\nH350i\nH372**\nH334\nH317\nH410\nH\n028-056-00-1\nnickel boride (NiB); [1]\ndinickel boride; [2]\ntrinickel boride; [3]\nnickel boride; [4]\ndinickel silicide; [5]\nnickel disilicide; [6]\ndinickel phosphide; [7]\nnickel boron phosphide [8]\n234-493-0 [1]\n234-494-6 [2]\n234-495-1 [3]\n235-723-2 [4]\n235-033-1 [5]\n235-379-3 [6]\n234-828-0 [7]\n- [8]\n12007-00-0 [1]\n12007-01-1 [2]\n12007-02-2 [3]\n12619-90-8 [4]\n12059-14-2 [5]\n12201-89-7 [6]\n12035-64-2 [7]\n65229-23-4 [8]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH372**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350i\nH372**\nH317\nH410\nH\n028-057-00-7\ndialuminium nickel tetraoxide; [1]\nnickel titanium trioxide; [2]\nnickel titanium oxide; [3]\nnickel divanadium hexaoxide; [4]\ncobalt dimolybdenum nickel octaoxide; [5]\nnickel zirkonium trioxide; [6]\nmolybdenum nickel tetraoxide; [7]\nnickel tungsten tetraoxide; [8]\nolivine, nickel green; [9]\nlithium nickel dioxide; [10]\nmolybdenum nickel oxide; [11]\n234-454-8 [1]\n234-825-4 [2]\n235-752-0 [3]\n257-970-5 [4]\n268-169-5 [5]\n274-755-1 [6]\n238-034-5 [7]\n238-032-4 [8]\n271-112-7 [9]\n- [10]\n- [11]\n12004-35-2 [1]\n12035-39-1 [2]\n12653-76-8 [3]\n52502-12-2 [4]\n68016-03-5 [5]\n70692-93-2 [6]\n14177-55-0 [7]\n14177-51-6 [8]\n68515-84-4 [9]\n12031-65-1 [10]\n12673-58-4 [11]\nCarc. 1A\nSTOT RE 1\nSkin Sens. 1\nH350i\nH372**\nH317\nGHS08\nGHS07\nDgr\nH350i\nH372**\nH317\nH\n028-058-00-2\ncobalt lithium nickel oxide\n442-750-5\n—\nCarc. 1A\nAcute Tox. 2 *\nSTOT RE 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH350i\nH330\nH372**\nH317\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH350i\nH330\nH372**\nH317\nH410\n029-014-00-5\nreaction mass of: 2,2'-[[cis-1,2-cyclohexanediylbis(nitrilomethylidene)]bis[phenolate]](2-)N,N',O,O'-copper complex;\n2,2'-[[trans-1,2-cyclohexanediylbis(nitrilomethylidyne)]bis[phenolate]](2-)N,N',O,O'-copper complex\n419-610-7\n171866-24-3\nSTOT RE 2 *\nAquatic Chronic 2\nH373**\nH411\nGHS08\nGHS09\nWng\nH373**\nH411\n030-009-00-5\nzinc-bis(4-(n-octyloxycarbonylamino)salicylate) dihydrate\n417-130-2\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n030-010-00-0\n2-dodec-1-enylbutanedioic acid, 4-methyl ester zinc salt\n430-740-3\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n030-012-00-1\naluminium-magnesium-zinc-carbonate-hydroxide\n423-570-6\n169314-88-9\nAquatic Chronic 3\nH412\n—\nH412\n030-015-00-8\ntetrazinc(2+)bis(hexacyanocobalt(3+))diacetate\n440-060-9\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n040-003-00-4\nreaction product of 3,5-di-tert-butylsalicylic acid and zirconium oxychloride, dehydrated, basic Zr: DTBS= 1,0: 1,0 to 1,0: 1,5\n430-610-6\n226996-19-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n042-005-00-0\nreaction mass of: mono- and di-glycerols of canola oil;\ncanola oil acid amide of branched 1,3-propanediamine,N-[3-(tridecyloxy)-propyl];\nN,N-diorgano dithiocarbamate molybdenum complex\n434-240-6\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n046-001-00-X\ntetraammine palladium (II) hydrogen carbonate\n425-270-0\n134620-00-1\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH302\nH373**\nH318\nH317\nH410\n047-002-00-8\npolyphosphoric acid, copper, sodium, magnesium, calcium, silver and zinc salt\n416-850-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n050-021-00-4\ndichlorodioctyl stannane\n222-583-2\n3542-36-7\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Chronic 3\nH331\nH372**\nH412\nGHS06\nGHS08\nDgr\nH331\nH372**\nH412\n050-022-00-X\ndibutyltin dichloride;\n(DBTC)\n211-670-0\n683-18-1\nMuta. 2\nRepr. 1B\nAcute Tox. 2 *\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH360FD\nH330\nH301\nH312\nH372**\nH314\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH341\nH360FD\nH330\nH301\nH312\nH372**\nH314\nH410\nSkin Corr. 1B; H314: C ≥ 5 %\nSkin Irrit. 2; H315: 0,01 % ≤ C < 5 %\nEye Dam. 1; H318: 3 % ≤ C < 5 %\nEye Irrit. 2; H319: 0,01 % ≤ C < 3 %\nM=10\n050-023-00-5\nreaction mass of: bis[(2-ethyl-1-oxohexyl)oxy]dioctyl stannane;\nbis[((2-ethyl-1-oxohexyl)oxy)dioctylstannyl]oxide;\nbis(1-phenyl-1,3-decanedionyl)dioctyl stannane;\n((2-ethyl-1-oxohexyl)oxy)-(1-phenyl-1,3-decanedionyl)dioctyl stannane\n422-920-5\n—\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\nM=10\n050-024-00-0\nreaction mass of: tri-p-tolyltin hydroxide;\nhexa-p-tolyl-distannoxane\n432-230-6\n—\nSTOT RE 1\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH372**\nH302\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH372**\nH302\nH315\nH318\nH317\nH410\n064-001-00-8\ngadolinium(III)sulfite trihydrate\n456-900-2\n51285-81-5\nAquatic Chronic 2\nH411\nGHS09\nH411\n078-010-00-X\ntetraammine platinum (II) hydrogen carbonate\n426-730-3\n123439-82-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n078-011-00-5\nhydroxydisulfito platinum(II) acid\n423-310-1\n61420-92-6\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Corr. 1A\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH373\nH314\nH334\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373\nH314\nH334\nH317\nH412\n078-012-00-0\nplatinum(IV) nitrate/nitric acid solution\n432-400-1\n—\nSkin Corr. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n082-012-00-6\nbarium calcium cesium lead samarium strontium bromide chloride fluoride iodide europium doped\n431-780-4\n199876-46-5\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373**\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH411\n601-070-00-0\nreaction mass of: branched icosane;\nbranched docosane;\nbranched tetracosane\n417-050-8\n151006-58-5\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n601-072-00-1\nreaction mass of: 1-(4-isopropylphenyl)-1-phenylethane;\n1-(3-isopropylphenyl)-1-phenylethane;\n1-(2-isopropylphenyl)-1-phenylethane\n430-690-2\n52783-21-8\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n601-075-00-8\n4,4'-bis(N-carbamoyl-4-methylbenzenesulfonamide)diphenylmethane\n418-770-5\n151882-81-4\nCarc. 2\nH351\nGHS08\nWng\nH351\n601-076-00-3\nethynyl cyclopropane\n425-430-1\n6746-94-7\nFlam. Liq. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH225\nH315\nH318\nH412\nGHS02\nGHS05\nDgr\nH225\nH315\nH318\nH412\n601-077-00-9\nreaction mass of: 1-heptyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane;\n1-nonyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane\n426-510-7\n196965-91-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n601-078-00-4\nreaction mass of: 1,7-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane;\n2,3-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane\n427-040-5\n—\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\n601-079-00-X\nreaction mass of: trans-trans-cyclohexadeca-1,9-diene;\ncis-trans-cyclohexadeca-1,9-diene\n429-620-3\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n601-080-00-5\nreaction mass of: sec-butylphenyl(phenyl)methane, mixed isomers;\n1-(sec-butylphenyl(phenyl)-2-phenylethane, mixed isomers;\n1-(sec-butylphenyl-1-phenylethane, mixed isomers\n431-100-6\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n601-081-00-0\ncyclohexadeca-1,9-diene\n431-730-1\n4277-06-9\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n601-082-00-6\nreaction mass of: endo-2-methyl-exo-3-methyl-exo-2-[(exo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane;\nexo-2-methyl-exo-3-methyl-endo-2-[(endo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane\n434-420-4\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\n601-083-00-1\n5-endo-hexyl-bicyclo[2.2.1]hept-2-ene\n435-000-3\n22094-83-3\nAsp. Tox. 1\nSkin Irrit. 2\nAquatic Chronic 4\nH304\nH315\nH413\nGHS08\nGHS07\nDgr\nH304\nH315\nH413\n601-084-00-7\nreaction mass of: 5-endo-butyl-bicyclo[2.2.1]hept-2-ene;\n5-exo-butyl-bicyclo[2.2.1]hept-2-ene (80:20)\n435-180-3\n—\nAsp. Tox. 1\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH304\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH304\nH315\nH410\n602-095-00-X\nalkanes, C14-17, chloro;\nchlorinated paraffins, C14-17\n287-477-0\n85535-85-9\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nEUH066\n602-098-00-6\n2-(3-bromophenoxy)tetrahydro-2H-pyran\n429-030-6\n57999-49-2\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n602-099-00-1\n3-(4-fluorophenyl)-2-methylpropionylchloride\n426-370-7\n—\nSkin Corr. 1A\nAcute Tox. 4 *\nAquatic Chronic 3\nH314\nH302\nH412\nGHS05\nGHS07\nDgr\nH314\nH302\nH412\nEUH014\nEUH029\n602-100-00-5\nreaction mass of: (R,R)-1,1,1,2,2,3,4,5,5,5-decafluoropentane;\n(S,S)-1,1,1,2,2,3,4,5,5,5-decafluoropentane\n420-640-8\n—\nAquatic Chronic 3\nH412\n—\nH412\n602-101-00-0\n2-chloro-4-fluoro-5-nitrophenyl (isobutyl)carbonate\n427-020-6\n141772-37-4\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373**\nH317\nH410\n602-102-00-6\n1,1,1,3,3-pentafluorobutane\n430-250-1\n406-58-6\nFlam. Liq. 2\nH225\nGHS02\nDgr\nH225\n602-103-00-1\n1-(chlorophenylmethyl)-2-methylbenzene\n431-450-1\n41870-52-4\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n602-104-00-7\n1,1,2,2,3,3,4-heptafluorocyclopentane\n430-710-1\n15290-77-4\nAquatic Chronic 3\nH412\n—\nH412\n602-105-00-2\nsodium 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanesulfinate\n422-100-7\n102061-82-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n602-106-00-8\n2-bromo-4,6-difluoroaniline\n429-430-0\n444-14-4\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n602-107-00-3\n3,3,4,4-tetrafluoro-4-iodo-1-butene\n439-500-2\n33831-83-3\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Chronic 2\nH302\nH315\nH411\nGHS07\nGHS09\nWng\nH302\nH315\nH411\n602-108-00-9\n(2,3,5,6-tetrafluorophenyl)methanol\n443-840-7\n4084-38-2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH302\nH319\nH317\nGHS07\nWng\nH302\nH319\nH317\n603-109-00-7\nreaction mass of: 1-ethoxy-1,1,2,3,3,3-hexafluoro-2-(trifluoromethyl)propane;\n1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane\n425-340-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n603-110-00-2\nreaction mass of: cis-2-isobutyl-5-methyl 1,3-dioxane;\ntrans-2-isobutyl-5-methyl 1,3-dioxane\n426-130-1\n166301-21-9\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n603-111-00-8\nreaction mass of: 1-(1,1-dimethylpropyl)-4-ethoxy-cis-cyclohexane;\n1-(1,1-dimethylpropyl)-4-ethoxy-trans-cyclohexane\n426-530-6\n—\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n603-112-00-3\ncyclopentyl 2-phenylethyl ether\n428-340-9\n—\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n603-113-00-9\n6-glycidyloxynapht-1-yl oxymethyloxirane\n429-960-2\n27610-48-6\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH341\nH312\nH315\nH317\nH412\nGHS08\nGHS07\nWng\nH341\nH312\nH315\nH317\nH412\n603-114-00-4\n9-(2-propenyloxy)tricyclo[5.2.1.0(2,6)]dec-3(or-4-)-ene\n430-830-2\n26912-64-1\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-115-00-X\nreaction mass of: O,O',O''-(methylsilanetriyl)tris(4-methyl-2-pentanone oxime) (3 stereoisomers)\n423-580-0\n—\nSTOT RE 2 *\nAquatic Chronic 4\nH373**\nH413\nGHS08\nWng\nH373**\nH413\n603-116-00-5\n(Z)-(2,4-difluorophenyl)piperidin-4-ylmethanone oxime monohydrochloride\n424-740-2\n138271-16-6\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n603-182-00-5\nreaction product of: saturated, monounsaturated and multiple unsaturated long-chained partly estrified alcohols of vegetable origin (Brassica napus L., Brassica rapa L., Helianthus annuus L., Glycine hispida, Gossypium hirsutum L., Cocos nucifera L., Elaeis guineensis) with O,O-diisobutyldithiophosphate and 2-ethylhexylamine and hydrogen peroxide\n428-630-5\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n603-188-00-8\nreaction mass of: 6,7-epoxy-1,2,3,4,5,6,7,8-octahydro-1,1,2,4,4,7-hexamethylnaphthalene;\n7,8-epoxy-1,2,3,4,6,7,8,8a-octahydro-1,1,2,4,4,7-hexamethylnaphthalene\n426-970-9\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-190-00-9\n8,8-dimethyl-7-isopropyl-6,10-dioxaspiro[4.5]decane\n424-030-2\n62406-73-9\nSkin Irrit. 2\nAquatic Chronic 3\nH315\nH412\nGHS07\nWng\nH315\nH412\n603-192-00-X\n(E,E)-3,7,11-trimethyldodeca-1,4,6,10-tetraen-3-ol\n423-240-1\n125474-34-2\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n603-193-00-5\ndisodium 9,10-anthracenedioxide\n426-030-8\n46492-07-3\nSkin Corr. 1A\nH314\nGHS05\nDgr\nH314\n603-194-00-0\n2-(2-aminoethylamino)ethanol;\n(AEEA)\n203-867-5\n111-41-1\nRepr. 1B\nSkin Corr. 1B\nSkin Sens. 1\nH360Fd\nH361\nH314\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH360Fd\nH361\nH314\nH317\nSTOT SE 3; H335: C ≥ 5 %\n603-200-00-1\n1-pentanol; [1]\n3-pentanol [2]\n200-752-1 [1]\n209-526-7 [2]\n71-41-0 [1]\n584-02-1 [2]\nFlam. Liq. 3\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nH226\nH332\nH335\nH315\nGHS02\nGHS07\nWng\nH226\nH332\nH335\nH315\n603-201-00-7\n(E)-(7R, 11R)-3,7,11,15-tetramethylhexadec-2-ene-1-ol\n416-120-5\n—\nSkin Irrit. 2\nAquatic Chronic 4\nH315\nH413\nGHS07\nWng\nH315\nH413\n603-202-00-2\n4,4,5,5,5-pentafluoropentan-1-ol\n421-360-9\n148043-73-6\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n603-203-00-8\n(1R,3S,7R,8R,10R,13R)-5,5,7,9,9,13-hexamethyl-4,6-dioxatetracyclo[6.5.1.01,10.03,7]tetradecane\n427-580-1\n—\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n603-204-00-3\nreaction mass of: 2,2'-(heptane-1,7-diyl)bis-1,3-dioxolane;\n2,2'-(heptane-1,6-diyl)bis-1,3-dioxolane\n428-110-8\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-205-00-9\n(1S-cis)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol hydrochloride\n426-200-1\n172015-79-1\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH372**\nH302\nH318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH372**\nH302\nH318\nH317\nH412\n603-206-00-4\n2,2-dichloro-1,3-benzodioxol\n426-850-6\n2032-75-9\nFlam. Liq. 3\nSkin Corr. 1A\nAcute Tox. 4 *\nSkin Sens. 1\nH226\nH314\nH302\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH314\nH302\nH317\nEUH014\n603-207-00-X\n2-isobutyl-2-isopropyl-1,3-dimethoxypropane\n430-800-9\n129228-21-3\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n603-208-00-5\n1,2-diethoxyethane\n211-076-1\n629-14-1\nFlam. Liq. 2\nRepr. 1A\nEye Irrit. 2\nH225\nH360Df\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH225\nH360Df\nH319\nEUH019\n603-209-00-0\nspinosad (ISO) (reaction mass of spinosyn A and spinosyn D in ratios between 95:5 to 50:50);\nreaction mass of 50-95 % of (2R, 3aS, 5aR, 5bS, 9S, 13S, 14R, 16aS, 16bR)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-14-methyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione and 50-5 % (2S, 3aR, 5aS, 5bS, 9S, 13S, 14R, 16aS, 16bS)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-4,14-dimethyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione; [1]\nspinosyn A; [2]\nspinosyn D [3]\n- [1]\n- [2]\n- [3]\n- [1]\n131929-60-7 [2]\n131929-63-0 [3]\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=10\n603-210-00-6\n2,4-diethyl-1,5-pentanediol\n429-310-8\n57987-55-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n603-211-00-1\n2,3-epoxypropyltrimethylammonium chloride … %;\nglycidyl trimethylammonium chloride … %\n221-221-0\n3033-77-0\nCarc. 1B\nMuta. 2\nRepr. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH341\nH361f***\nH312\nH302\nH373**\nH318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH350\nH341\nH361f***\nH312\nH302\nH373**\nH318\nH317\nH412\nB\n603-212-00-7\n1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran;\ngalaxolide;\n(HHCB)\n214-946-9\n1222-05-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n603-213-00-2\n2-methoxy-2-methylbutane;\ntert-amyl methyl ether\n213-611-4\n994-05-8\nFlam. Liq. 2\nAcute Tox. 4 *\nSTOT SE 3\nH225\nH302\nH336\nGHS02\nGHS07\nDgr\nH225\nH302\nH336\n603-214-00-8\n1,1-diisopropoxycyclohexane\n413-740-8\n1132-95-2\nSkin Corr. 1B\nH314\nGHS05\nDgr\nH314\n603-215-00-3\n1-hydroxy-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)\n418-330-2\n162241-33-0\nExpl. 1.1****\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH302\nH373**\nH318\nH317\nH400\nH410\nGHS01\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH302\nH373**\nH318\nH317\nH410\n603-216-00-9\ncis-1-amino-2,3-dihydro-1H-inden-2-ol\n422-660-2\n7480-35-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n603-217-00-4\n2,4,6-tri-tert-butylphenyl 2-butyl-2-ethyl-1,3-propanediolphosphite\n423-560-1\n161717-32-4\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n603-220-00-0\n1-{]benzyl[}2-(2-methoxyphenoxy)ethyl{]amino[}-3-(9H-carbazol-4-yloxy)propan-2-ol\n432-890-5\n72955-94-3\nAquatic Chronic 4\nH413\n—\nH413\n603-221-00-6\n1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride;\n[containing < 0,1 % 4-chloroaniline (EC No 203-401-0)]\n433-580-2\n214353-17-0\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH302\nH314\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH411\n603-221-01-3\n1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride;\n[containing ≥ 0,1 % 4-chloroaniline (EC No 203-401-0)]\n433-580-2\n214353-17-0\nCarc. 1B\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 2\nH350\nH302\nH314\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH302\nH314\nH411\n603-222-00-1\n(2R, 3S, 4R, 5R, 7R, 9R, 10R, 11S, 12S, 13R)-10-[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclotetradecane\n433-820-6\n118058-74-5\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n603-223-00-7\n2-cyclopentylidene cyclopentanol;\n1,1'-bi(cyclopentyliden)-2-ol\n434-270-1\n6261-30-9\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH315\nH318\nH412\nGHS05\nDgr\nH315\nH318\nH412\n603-224-00-2\n3-ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-(trifluoromethyl)-hexane\n435-790-1\n297730-93-9\nAquatic Chronic 4\nH413\n—\nH413\n603-225-00-8\nerythromycin A9-oxime (E);\n(3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-((2,6-didesoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopiranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino-β-d-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxime (E)\n437-070-0\n13127-18-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-226-00-3\n4,4'(4-(4-methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzene-1,3-diol\n444-500-0\n1440-00-2\nAquatic Chronic 3\nH412\n—\nH412\n603-227-00-9\nα-hydro-ω-[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethanediyl)] ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1);\nreaction product of: α-hydro-ω-((chlorocarbonyl)oxy)-poly(oxy(methyl-1,2-ethanediyl)) ether with 2,2-bis(hydroxymethyl)-1,3-propanediol with potassium 1,1-dimethylethylperoxalate\n445-060-2\n203574-04-3\n****\nAquatic Acute 1\nAquatic Chronic 1\n****\nH400\nH410\n****\nGHS09\nWng\n****\nH410\n603-228-00-4\n(+/–)-(R*, R*)-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran;\n6-fluoro-2-(2-oxiranyl)chromane\n419-620-1\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n603-229-00-X\nsodium (Z)-3-chloro-3-(4-chlorophenyl)-1-hydroxy-2-propene-1-sulfonate\n420-800-7\n—\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\n603-230-00-5\n2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan\n440-030-5\n—\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 4\nH315\nH318\nH413\nGHS05\nDgr\nH315\nH318\nH413\n603-231-00-0\n(S)-1,1-diphenyl-1,2-propanediol\n443-220-6\n—\nAquatic Chronic 3\nH412\n—\nH412\n603-232-00-6\n3,3,8,8,10,10-hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane\n444-420-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n603-233-00-1\nreaction mass of: 4-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol;\n4-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol;\n1-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol;\n1-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol;\n(E)-4-(3a,4,5,6,7,7a-hexahydro-1H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol;\n(E)-4-(3a,4,5,6,7,7a-hexahydro-3H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol\n444-430-0\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n603-234-00-7\n(1R, 4R)-4-methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-ene\n444-480-3\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n604-071-00-4\n4,4'-(1-{]4-[}1-(4-hydroxyphenyl)-1-methylethyl{]phenyl[}ethylidene)diphenol\n425-600-3\n110726-28-8\nAquatic Chronic 4\nH413\n—\nH413\n604-072-00-X\n1,2-bis(phenoxymethyl)benzene\n428-620-0\n10403-74-4\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-073-00-5\n(E)-3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol\n428-010-4\n82413-20-5\nCarc. 2\nRepr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH360F***\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360F***\nH317\nH410\n604-074-00-0\ntetrabromobisphenol-A;\n2,2', 6,6'-tetrabromo-4,4'-isopropylidenediphenol\n201-236-9\n79-94-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-075-00-6\n4-(1,1,3,3-tetramethylbutyl)phenol;\n4-tert-octylphenol\n205-426-2\n140-66-9\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH315\nH318\nH410\nM=10\n604-076-00-1\nphenolphthalein\n201-004-7\n77-09-8\nCarc. 1B\nMuta. 2\nRepr. 2\nH350\nH341\nH361f***\nGHS08\nDgr\nH350\nH341\nH361f***\nCarc. 1A; H350: C ≥ 1 %\n604-077-00-7\n2-benzotriazol-2-yl-4-methyl-6-(2-methylallyl)phenol\n419-750-9\n98809-58-6\nAquatic Chronic 4\nH413\n—\nH413\n604-079-00-8\n4,4'-(1,3-phenylene-bis(1-methylethylidene))bis-phenol\n428-970-4\n13595-25-0\nRepr. 2\nSkin Sens. 1\nAquatic Chronic 2\nH361f***\nH317\nH411\nGHS08\nGHS09\nWng\nH361f***\nH317\nH411\n604-080-00-3\n4-fluoro-3-trifluoromethylphenol\n432-560-0\n61721-07-1\nAcute Tox. 4 *\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Chronic 2\nH332\nH314\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH332\nH314\nH317\nH411\n604-081-00-9\n1,1-bis(4-hydroxyphenyl)-1-phenylethane\n433-130-5\n1571-75-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n604-082-00-4\n2-chloro-6-fluoro-phenol\n433-890-8\n2040-90-6\nMuta. 1B\nRepr. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH340\nH361f***\nH302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH340\nH361f***\nH302\nH314\nH317\nH411\n604-083-00-X\n4,4'-sulfonylbisphenol, polymer with ammonium chloride(NH4Cl), pentachlorophosphorane and phenol\n439-270-3\n260408-02-4\nAquatic Chronic 4\nH413\n—\nH413\n604-084-00-5\n1-ethoxy-2,3-difluorobenzene\n441-000-4\n121219-07-6\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n604-087-00-1\nreaction mass of: 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)monoester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol;\n1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)diester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol;\n1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)triester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol\n433-640-8\n—\nPyr. Sol. 1\nAquatic Chronic 4\nH250\nH413\nGHS02\nDgr\nH250\nH413\nEUH044\n604-089-00-2\n2-methyl-5-tert-butylthiophenol\n444-970-7\n—\nFlam. Liq. 3\nRepr. 2\nSTOT RE 2 *\nAsp. Tox. 1\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nSTOT SE 3\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH361d***\nH373**\nH304\nH319\nH315\nH317\nH336\nH400\nH410\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH361d***\nH373**\nH304\nH319\nH315\nH317\nH336\nH410\n605-023-00-5\n5-chloro-2-(4-chlorophenoxy)phenol\n429-290-0\n3380-30-1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n605-024-00-0\n2-bromo-5-hydroxy-4-methoxybenzaldehyde\n426-540-0\n2973-59-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-032-00-4\n3-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-(E)-2-propenal\n425-370-4\n93957-50-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n605-033-00-X\nreaction mass of: 3,7,11-trimethyl-cis-6,10-dodecadienal;\n3,7,11-trimethyl-trans-6,10-dodecadienal\n425-910-9\n32480-08-3\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH410\n605-034-00-5\nreaction mass of: (1RS, 2RS, 3SR, 6RS, 9SR)-9-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde;\n(1RS, 2RS, 3RS, 6RS, 8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde;\n(1RS, 2RS, 4SR, 6RS, 8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-4-carbaldehyde\n429-860-9\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n605-035-00-0\n(E)-3-(4-(4-fluorophenyl)-5-methoxymethyl-2,6-bis(1-methoxymethyl)pyridin-3-yl)prop-2-enal\n426-330-9\n177964-68-0\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH319\nH317\nH413\nGHS07\nWng\nH319\nH317\nH413\n605-036-00-6\n2-bromomalonaldehyde\n430-470-6\n2065-75-0\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n605-037-00-1\ntrans-3-[2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde;\n3-[(E)-2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde\n421-800-1\n120578-03-2\nAquatic Chronic 4\nH413\n—\nH413\n605-038-00-7\n3-methyl-5-phenylpentan-1-al\n433-900-0\n55066-49-4\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH315\nH317\nH411\n605-039-00-2\n3,4-dihydroxy-5-nitrobenzaldehyde\n441-810-8\n116313-85-0\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n606-074-00-6\nreaction mass of: (1R*, 2S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethylnaphthalene;\n(2R*, 3S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethylnaphthalene\n425-570-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-090-00-3\n1-[3-[(dimethylamino)methyl]-4-hydroxyphenyl]ethanone\n430-920-1\n73096-98-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n606-093-00-X\n5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one\n414-470-3\n95885-13-5\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n606-094-00-5\nN-[ethyl(3-methylbutyl)amino]-3-methyl-1-phenyl-spiro[[1]benzo-pyrano[2,3-c]pyrazole-4(1H), 1'(3'H)-isobenzofuran]-3'-one\n417-460-7\n—\nAquatic Chronic 4\nH413\n—\nH413\n606-095-00-0\n(R,S)-2-azabicyclo[2.2.1]hept-5-en-3-one\n421-830-3\n49805-30-3\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n606-096-00-6\n3-(6-O-(6-desoxy-α-l-mannopyranosyl-O-(α-d-glucopyranosyl)-(β-d-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one\n424-170-4\n130603-71-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n606-097-00-1\n2,2''-dihydroxy-4,4''-(2-hydroxy-propane-1,3-diyldioxy)dibenzophenone\n424-210-0\n23911-85-5\nAquatic Chronic 4\nH413\n—\nH413\n606-098-00-7\n1-benzyl-5-(hexadecyloxy)-2,4-imidazolidinedione\n431-220-9\n158574-65-3\nAquatic Chronic 4\nH413\n—\nH413\n606-099-00-2\n5-methoxy-4'-(trifluoromethyl)valerophenone\n425-000-1\n61718-80-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-100-00-6\n2-butyryl-3-hydroxy-5-thiocyclohexan-3-yl-cyclohex-2-en-1-one\n425-150-8\n94723-86-1\nRepr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH360F***\nH302\nH317\nH412\nGHS08\nGHS07\nDgr\nH360F***\nH302\nH317\nH412\n606-101-00-1\nreaction mass of: 1,5-bis[(2-ethylhexyl)amino]-9,10-anthracenedione;\n1-[(2-ethylhexyl)amino]-5-[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione;\n1,5-bis[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione;\n1-[(2-ethylhexyl)amino]-5-[(3-methoxypropyl)amino]-9,10-anthracene dione;\n1-[3-[(2-ethylhexyl)oxy]propyl]amino-5-[(3-methoxypropyl)amino]-9,10-anthracenedione;\n1,5-bis[(3-methyloxypropyl)amino]-9,10-anthracenedione\n426-050-7\n165038-51-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n606-102-00-7\n4-(3-triethoxysilylpropoxy)-2-hydroxybenzophenone\n431-490-8\n79876-59-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-103-00-2\n1-(4-(trans-4-ethylcyclohexyl)phenyl)ethanone\n426-460-6\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n606-104-00-8\n1-(4-(trans-4-pentylcyclohexyl)phenyl)ethanone\n426-830-7\n78531-59-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-105-00-3\n3,4,3', 4'-tetraphenyl-1,1'-ethandiylbispyrol-2,5-dione\n431-500-0\n226065-73-2\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-106-00-9\n1-(4-(trans-4-butylcyclohexyl)phenyl)ethanone\n427-320-7\n83626-30-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-107-00-4\n8-azaspiro[4.5]decane-7,9-dione\n427-770-4\n1075-89-4\nAcute Tox. 3 *\nAquatic Chronic 2\nH301\nH411\nGHS06\nGHS09\nDgr\nH301\nH411\n606-108-00-X\n1,1,1,2,2,4,5,5,5-nonafluoro-4-(trifluoromethyl)-3-pentanone\n436-710-6\n756-13-8\nAquatic Chronic 3\nH412\n—\nH412\n606-109-00-5\n2-(4-methyl-3-pentenyl)anthraquinone\n428-320-1\n71308-16-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 4\nH302\nH317\nH314\nGHS07\nWng\nH302\nH317\nH314\n606-110-00-0\n5-ethoxy-5H-furan-2-one\n428-330-4\n2833-30-9\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nH314\nH312\nH302\nH373**\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH314\nH312\nH302\nH373**\nH317\n606-111-00-6\n5-amino-6-methyl-1,3-dihydrobenzoimidazol-2-one\n428-410-9\n67014-36-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n606-112-00-1\n(4aR*, 8aR*)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-one\n428-690-2\n1668-86-6\nAcute Tox. 4 *\nEye Irrit. 2\nAquatic Chronic 3\nH302\nH319\nH412\nGHS07\nWng\nH302\nH319\nH412\n606-113-00-7\n1-[4-(4-benzoylphenylsulfanyl)phenyl]-2-methyl-2-(4-methylphenylsulfonyl)propan-1-one\n429-040-0\n272460-97-6\nEye Dam. 1\nAquatic Chronic 4\nH318\nH314\nGHS05\nDgr\nH318\nH314\n606-114-00-2\n4,4', 5,5', 6,6', 7,7'-octachloro-(2,2')biisoindolyl-1,1', 3,3'-tetraone\n429-150-9\n67887-47-2\nAquatic Chronic 4\nH413\n—\nH413\n606-115-00-8\nprofoxydim (ISO);\n2-{](EZ)-1-[}(2RS)-2-(4-chlorophenoxy)propoxyimino{]butyl[}-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one\n—\n139001-49-3\nCarc. 2\nRepr. 2\nSkin Sens. 1\nH351\nH361d\nH317\nGHS08\nGHS07\nWng\nH351\nH361d\nH317\n606-116-00-3\ntepraloxydim (ISO);\n(RS)-(EZ)-2-{]1-[}(2E)-3-chloroallyloxyimino{]propyl[}-3-hydroxy-5-perhydropyran-4-ylcyclohex-2-en-1-one\n—\n149979-41-9\nCarc. 2\nRepr. 2\nH351\nH361fd\nGHS08\nWng\nH351\nH361fd\n606-117-00-9\n2,6-bis(1,1-dimethylethyl)-4-(phenylenemethylene)cyclohexa-2,5-dien-1-one\n429-460-4\n7078-98-0\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-118-00-4\nN-(1,3-dimethylbutyl)-N'-(phenyl)-1,4-benzoquinonediimine\n429-640-2\n52870-46-9\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH410\n606-119-00-X\n(E)-3-methyl-5-cyclopentadecen-1-one\n429-900-5\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n606-120-00-5\n2,5-dihydroxy-5-methyl-3-(morpholin-4-yl)-2-cyclopenten-1-one\n430-170-5\n114625-74-0\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n606-121-00-0\n(+)-(1S, 2S, 3S, 5R)-2,6,6-trimethylbicyclo[3.1.1]heptane-3-spiro-1'-(cyclohex-2'-en-4'-one)\n430-460-1\n133636-82-5\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n606-122-00-6\n3-(2-bromopropionoyl)-4,4-dimethyl-1,3-oxazolan-2-one\n430-820-8\n114341-88-7\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH302\nH373**\nH315\nH318\nH317\nH410\n606-123-00-1\n4-hexadecyl-1-phenylpyrazolidin-3-one\n430-840-7\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n606-124-00-7\n1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)-1,3-propanedione\n421-080-7\n161462-35-7\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n606-125-00-2\n1-benzylimidazolidine-2,4-dione\n421-340-1\n6777-05-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n606-126-00-8\n1,4-bis(2,3-dihydroxypropylamino)anthraquinone\n421-470-7\n99788-75-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n606-128-00-9\n2,2'-(1,3-phenylene)bis[5-chloro-1H-isoindole]-1,3(2H)-dione\n422-650-8\n148935-94-8\nAquatic Chronic 4\nH413\n—\nH413\n606-129-00-4\n5-amino-[2S-di(methylphenyl)amino]-1,6-diphenyl-4Z-hexen-3-one;\n(2S, 4Z)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one\n423-090-7\n156732-13-7\nAquatic Chronic 4\nH413\n—\nH413\n606-130-00-X\n4-(1,4-dioxa-spiro[4.5]dec-8-yl)-cyclohexanone\n423-860-2\n56309-94-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-131-00-5\ncyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione\n427-230-8\n5571-36-8\nRepr. 1B\nSTOT RE 2 *\nAquatic Chronic 2\nH360F***\nH373**\nH411\nGHS08\nGHS09\nDgr\nH360F***\nH373**\nH411\n606-132-00-0\n(6β)-6,19-epoxyandrost-4-ene-3,17-dione\n433-490-3\n6563-83-3\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n606-134-00-1\nandrosta-1,4,9(11)-triene-3,17-dione\n433-560-3\n15375-21-0\nRepr. 2\nH361f***\nGHS08\nWng\nH361f***\n606-135-00-7\ncyclohexadecanone\n438-930-8\n2550-52-9\nAquatic Chronic 4\nH413\n—\nH413\n606-136-00-2\n(3S, 6R, 9S, 12R, 15S, 18R, 21S, 24R)-6,18-dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo-tetracosane-2,5,8,11,14,17,20,23-octaone\n444-350-6\n133413-70-4\nEye Irrit. 2\nAquatic Chronic 4\nH319\nH413\nGHS07\nWng\nH319\nH413\n606-137-00-8\ntrans-7,7'-dimethyl-(4H, 4H')-(2,2')bi[benzo[1,4]thiazinylidene]-3,3'-dione\n444-750-0\n211387-26-7\nAquatic Chronic 4\nH413\n—\nH413\n606-138-00-3\n(2-butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanone\n444-800-1\n141645-23-0\nFlam. Liq. 3\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH226\nH302\nH373**\nH315\nH318\nH317\nH400\nH410\nGHS02\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH226\nH302\nH373**\nH315\nH318\nH317\nH410\nM=10\n606-139-00-9\n(S)-4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one\n444-830-5\n124379-29-9\nAquatic Chronic 4\nH413\n—\nH413\n606-140-00-4\n2-hydroxy-1-(4-(4-(2-hydroxy-2-methylpropionyl)benzyl)phenyl)-2-methylpropan-1-one\n444-860-9\n474510-57-1\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n606-141-00-X\nsodium 3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolate\n418-410-7\n—\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n606-142-00-5\nreaction mass of: (1RS, 2SR, 7SR, 8SR, E) 9 and 10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one;\n(1RS, 2SR, 7SR, 8SR, Z)-10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one;\n(1RS, 2SR, 7SR, 8SR, Z)-9-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one\n434-290-9\n—\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-417-00-2\n3-chloropropyl chloroformiate\n425-770-9\n628-11-5\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH331\nH302\nH373**\nH315\nH318\nH317\nGHS06\nGHS05\nGHS08\nDgr\nH331\nH302\nH373**\nH315\nH318\nH317\n607-428-00-2\ntetrasodium ethylene diamine tetraacetate\n200-573-9\n64-02-8\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n607-429-00-8\nedetic acid;\n(EDTA)\n200-449-4\n60-00-4\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-471-00-7\n1,6-bis((dibenzylthiocarbamoyl)disulfanyl)hexane\n429-280-6\n151900-44-6\nAquatic Chronic 4\nH413\n—\nH413\n607-473-00-8\npentaerythritol, dipentaerythritol, fatty acids, C6-10, mixed esters with adipic acid, heptanoic acid and isostearic acid\n426-590-3\n187412-41-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-477-00-X\n(1α5α6α)-6-nitro-3-benzyl-3-azabicyclo[3.1.0]hexane methanesulfonate salt\n426-740-8\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-481-00-1\nreaction mass of: trihexyl citrate;\ndihexyloctyl citrate;\ndioctylhexyl citrate;\ndihexyldecyl citrate\n430-290-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-482-00-7\nN-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-l-alanyl-N-carboxyanhydride\n430-360-8\n84793-24-8\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-483-00-2\n1,2-benzenedicarboxylic acid;\ndi-C6-8-branched alkylesters, C7-rich\n276-158-1\n71888-89-6\nRepr. 1B\nH360D***\nGHS08\nDgr\nH360D***\n607-484-00-8\nethyl 2-{][}3-acetylamino-4-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)phenyl{]ethylamino[}propionate\n430-480-0\n221452-67-1\nAquatic Chronic 4\nH413\n—\nH413\n607-485-00-3\n(3S-trans)-phenyl-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinecarboxylate\n430-510-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-486-00-9\npotassium sodium 5'-(6-chloro-4-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-4'-hydroxy-2,3'-azodinaphthalene-1,2', 5,7'-disulfonate\n402-110-8\n110081-40-8\nAquatic Chronic 3\nH412\n—\nH412\n607-491-00-6\nreaction mass of: diester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:2);\ntriester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:3)\n427-140-9\n—\nCarc. 2\nH351\nGHS08\nWng\nH351\n607-504-00-5\ndiammonium 1-hydroxy-2-(4-(4-carboxyphenylazo)-2,5-dimethoxyphenylazo)-7-amino-3-naphthalenesulfonate\n422-670-7\n—\nRepr. 1A\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH361f\nH301\nH373**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH361f\nH301\nH373**\nH410\n607-509-00-2\n2-phenoxyethyl 4-aminobenzoate\n430-880-5\n88938-23-2\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-510-00-8\n(2S, 5R)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide\n427-200-4\n76646-91-8\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH302\nH315\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH317\n607-511-00-3\nreaction mass of: 4-[(3-decyloxypropyl)(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)amino]-4-oxobutyric acid;\n4-[(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)(3-octyloxypropyl)amino]-4-oxobutyric acid\n423-750-4\n—\nEye Irrit. 2\nAquatic Chronic 2\nH319\nH411\nGHS07\nGHS09\nWng\nH319\nH411\n607-514-00-X\npotassium N-(1-methoxy-1-oxobut-2-en-3-yl)valinate\n427-240-2\n134841-35-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-518-00-1\n3-oxoandrost-4-ene-17-β-carboxylic acid\n414-990-0\n302-97-6\nRepr. 1A\nAquatic Chronic 4\nH361f\nH413\nGHS08\nDgr\nH361f\nH413\n607-519-00-7\npoly-[((4-((4-ethyl-ethylene)amino)phenyl)-((4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)cyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]\n427-280-0\n176429-27-9\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH335\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH335\nH315\nH318\nH410\n607-520-00-2\nreaction mass of: sodium 4,5-dihydro-2-[(propionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate;\ndisodium 4,5-dihydro-2-[(dipropionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate\n427-740-0\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-521-00-8\ntetraethyl N,N'-(methylenedicyclohexane-4,1-diyl)bis-dl-aspartate\n429-270-1\n136210-30-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-522-00-3\nsodium salt of the polymer of: sodium 2-methyl-buta-1,3-diene-1-sulfonate with acrylic acid and 2-hydroxyethyl-2-methylacrylate\n429-720-7\n184246-86-4\nAquatic Chronic 3\nH412\n—\nH412\n607-523-00-9\nreaction mass of mono to tetra(lithium and/or sodium)3-amino-10-[4-(4-amino-3-sulfonatoanilino)-6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to tetra(lithium and/or sodium)3-amino-10-[4,6-bis(4-amino-3-sulfonatoanilino)-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to penta(lithium and/or sodium)10,10'-diamino-6,6', 13,13'-tetrachloro-3,3'-[6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10-amino-6,6', 13,13'-tetrachloro-10'[4-(4-amino-3-sulfonatoanilino)-[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10,10'-diamino-6,6', 3,3'[(2-sulfonato)-1,4-phenylenediiminobis[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate\n430-200-7\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-524-00-4\ntall oil 2-[(tetrahydro-2H-pyran-2-yl) thio]ethyl esters\n430-310-5\n—\nAquatic Chronic 4\nH413\nH413\n607-525-00-X\n(Z)-2-methoxymino-2-[2-(tritylamino)thiazol-4-yl]acetic acid\n431-520-1\n64485-90-1\nFlam. Sol. 1****\nCarc. 2\nAquatic Chronic 3\nH228\nH351\nH412\nGHS02\nGHS08\nDgr\nH228\nH351\nH412\n607-528-00-6\n(S)-3-methyl-2-(2-oxotetrahydropyrimidine-1-yl)butyric acid\n430-900-2\n192725-50-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-529-00-1\nbenzyl cis-4-ammonium-4'-toluenesulfonato-1-cyclohexanecarboxylate\n426-070-6\n67299-45-0\nAquatic Chronic 3\nH412\n—\nH412\n607-530-00-7\nreaction mass of isomers of: C7-9-alkyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate\n406-040-9\n125643-61-0\nAquatic Chronic 4\nH413\n—\nH413\n607-531-00-2\nmethyl 3-amino-4,6-dibromo-2-methyl-benzoate\n425-190-6\n119916-05-1\nSTOT RE 2 *\nAquatic Chronic 2\nH373**\nH411\nGHS08\nGHS09\nWng\nH373**\nH411\n607-532-00-8\n(S)-1-[2-tert-butoxycarbonyl-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxylic acid, cyclohexylamine salt\n425-510-4\n167944-94-7\nAquatic Chronic 3\nH412\n—\nH412\n607-533-00-3\npentasodium monohydrogen 6-chloro-3,10-bis[2-[4-chloro-6-(2,4-disulfophenylamino)-1,3,5-triazin-2-yl-amino]ethylamino]-13-ethylbenzo[5.6][1.4]oxazino[2,3-b]phenoxazine-4,11-disulfonate\n414-910-4\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-534-00-9\nethyl 2-(3-benzoylphenyl)propanoate\n414-920-9\n60658-04-0\nAcute Tox. 3 *\nSTOT RE 1\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH372**\nH317\nH411\nGHS06\nGHS08\nGHS09\nDgr\nH301\nH372**\nH317\nH411\n607-535-00-4\npotassium 4-iodo-2-sulfonato-benzoic acid\n426-620-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-536-00-X\n(2,6-xylyloxy) acetic acid\n430-910-7\n13335-71-2\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n607-537-00-5\nisopropylammonium 2-(3-benzoylphenyl)propionate\n417-970-1\n—\nAcute Tox. 3 *\nAcute Tox. 4 *\nSTOT RE 1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH312\nH372**\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH312\nH372**\nH318\nH410\n607-539-00-6\npropyl((4-(5-oxo-3-propylisoxazolidin-4-ylidenmethin)phenyl)propoxycarbonylmethyleneamino)acetate\n431-000-2\n198705-81-6\nAquatic Chronic 4\nH413\n—\nH413\n607-540-00-1\n1-(mercaptomethyl)cyclopropylacetic acid\n420-240-3\n162515-68-6\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH314\nH312\nH302\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH312\nH302\nH317\nH411\n607-541-00-7\n[(1-methyl-1,2-ethanediyl)bis[nitrilobis(methylene)]]tetrakis(phosphonic acid)\n421-940-1\n28698-31-9\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n607-542-00-2\nmethyl 2-(4-butanesulfonamidophenoxy)tetradecanoate\n422-110-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-543-00-8\npoly-[((4-((4-(ethyl-ethylene)amino)phenyl)-(4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)-3-methylcyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]\n427-480-8\n176429-22-4\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH335\nH315\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH335\nH315\nH318\nH410\n607-544-00-3\nethyl 6,8-difluoro-1-(formylmethylamino)-1,4-dihydro-7-(4-methyl)piperazin-1-yl)-4-oxo-quinoline-3-carboxylate\n427-490-2\n158585-86-5\nAquatic Chronic 3\nH412\n—\nH412\n607-545-00-9\n1,2-dimethyl-3-(1-methylethenyl)cyclopentyl acetate\n424-070-0\n94346-09-5\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-546-00-4\nreaction mass of: methyl {][}5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl{]methoxycarbonylmethylamino[}acetate;\nmethyl {][}5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl{]ethoxycarbonylmethylamino[}acetate\n424-290-7\n188070-47-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-547-00-X\n18-methylnonadecyl 2,2 -dimethylpropanoate\n424-370-1\n125496-22-2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n607-548-00-5\n1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone methanesulfonate\n431-010-7\n154486-26-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-549-00-0\nmethyl (E)-2((3-(1,3-benzodioxol-5-yl)-2-methyl-1-propenyl)amino)benzoate\n424-430-7\n125778-19-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-550-00-6\n2-amino-4-bromo-5-chlorobenzoic acid\n424-700-4\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH410\nGHS05\nDgr\nH318\nH410\n607-551-00-1\ntetrabutylammonium 2-amino-6-iodopurinate\n424-710-9\n156126-48-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH312\nH302\nH373**\nH315\nH318\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH312\nH302\nH373**\nH315\nH318\nH317\nH411\n607-552-00-7\nhexadecyl 3-amino-4-isopropoxybenzoate\n424-830-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-553-00-2\n7-amino-4-hydroxy-2-naphthalenesulfonic acid, coupled with 5 (or 8) -amino-8 (or 5)-[[4-[[4-[[4-amino-6(or 7)-sulfo-1-naphthyl]azo]phenyl]amino]-3-sulfophenyl]azo]-2-naphthalenesulfonic acid and 4-hydroxy-7-(phenylamino)-2-naphthalenesulfonic acid, sodium salt\n424-850-0\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-554-00-8\n2,4-diamino-5-[4-[(2-sulfoxyl ethyl)sulfonyl]phenylazo]benzenesulfonic acid\n424-870-1\n27624-67-5\nExpl. 1.1\nEye Dam. 1\nAquatic Chronic 3\nH201\nH318\nH412\nGHS01\nGHS05\nDgr\nH201\nH318\nH412\n607-555-00-3\n1,1,3,3-tetramethylbutylperoxypivalate\n424-980-8\n22288-41-1\nFlam. Liq. 2\nOrg. Perox. D\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH225\nH242\nH315\nH317\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH225\nH242\nH315\nH317\nH411\n607-556-00-9\n2-acetoxymethylene-4-acetylphenylacetate\n425-160-2\n24085-06-1\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH318\nH317\nH400\nH410\nGHS05 GHS08 GHS07 GHS09 Dgr\nH302\nH373**\nH318\nH317\nH410\n607-557-00-4\nsalt of: (1S-cis)-1-amino-2,3-dihydro-1H-inden-2-ol and [R-[R*R*]]-2,3-dihydroxybutanedioic acid\n425-210-3\n169939-84-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-558-00-X\n2S-isopropyl-5R-methyl-1R-cyclohexyl (2R, 5S)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1.3]-oxathiolane-2-carboxylate\n425-250-1\n147027-10-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-559-00-5\ncoconut oil, reaction products with glycerol esters of 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid\n425-400-6\n179986-09-5\nAquatic Chronic 4\nH413\n—\nH413\n607-560-00-0\n(R,S)-2-butyloctanedioic acid\n431-210-4\n50905-10-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-561-00-6\nsodium 4-hydroxy-3-(N'-(2-(2-hydroxyethylenesulfonyl)ethylene)ureido)-5-nitrobenzenesulfonate\n425-460-3\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-562-00-1\nreaction mass of: (2R, 3R)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate;\n(2S, 3S)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate\n425-530-3\n98769-75-6\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n607-563-00-7\n5,7-dichloro-4-hydroxyquinoline-3-carboxylic acid\n431-250-2\n171850-30-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-564-00-2\n1,6-hexanediammonium, sodium 5-sulfato-1,3-benzenedicarboxylate\n425-730-0\n51178-75-7\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-565-00-8\n3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate\n425-820-1\n88150-42-9\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH373**\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH373**\nH318\nH410\n607-566-00-3\nreaction mass of: dodecylphenyl dodecylhydroxybenzenecarboxylate;\nbis(dodecylphenyl)dodecyl hydroxybenzenedicarboxylate\n426-140-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-567-00-9\npotassium 3-iodo-6-methylbenzenesulfonate\n426-300-5\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-568-00-4\npotassium 2-chloro-3-(benzyloxy)propionate\n426-350-8\n138666-92-9\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\n607-569-00-X\nreaction mass of: sodium 2-amino-4-(2,6-difluoropyrimidin-4-ylamino)benzenesulfonate;\nsodium 2-amino-4-(4,6-difluoropyrimidin-4-ylamino)benzenesulfonate\n426-470-0\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-570-00-5\nsodium (6R-trans)-7-amino-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monohydrate\n426-520-1\n71420-85-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-571-00-0\n2-cyclopentene-1-acetic acid, 3-hydroxy-2-pentyl-, methyl ester acetate\n431-400-7\n57374-49-9\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-572-00-6\ndiethyl thiophosphoryl (Z)-(2-aminothiazol-4-yl)methoxyimino acetate\n426-790-0\n162208-27-7\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH312\nH302\nH373**\nH317\nH410\n607-573-00-1\nreaction mass of: disodium 7-(2,4-difluoropyrimidin-6-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate;\ndisodium 7-(4,6-difluoropyrimidin-2-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate\n426-840-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-574-00-7\n[1R-(1-α, 2β,5α)]-mono[5-methyl-2-(1-methylethyl)cyclohexyl]butanedioate\n426-890-4\n77341-67-4\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-575-00-2\n4-(5-(5-[1-(4-carboxyphenyl)hexahydro-2,4,6-trioxopyrimidin-5-ylidene]penta-1,3-dienyl)-1,2,3,4-tetrahydro-6-hydroxy-2,4-dioxopyrimidin-1-yl)benzoic acid-triethylamine salt\n426-900-7\n—\nSTOT SE 3\nAquatic Chronic 3\nH335\nH412\nGHS07\nWng\nH335\nH412\n607-576-00-8\nbranched, octyl 3-[3,5-di(tert-butyl)-4-hydroxyphenyl]propanoate\n427-030-0\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-577-00-3\n(2R*, 3S*)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (1R)-10-camphorsulfonate\n427-100-0\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n607-578-00-9\nethyl 4-((4-diethylamino-2-methylphenyl)imino)-4,5-dihydro-1-isopropyl-5-oxo-1H-pyrazole-3-carboxylate\n427-110-5\n—\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 4\nH302\nH373**\nH413\nGHS08\nGHS07\nWng\nH302\nH373**\nH413\n607-579-00-4\ndiethyl[(p-ethoxyanilino)methylene]malonate\n431-430-0\n103976-28-9\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n607-580-00-X\nethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate\n422-360-1\n100491-29-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-581-00-5\nethyl 2-ethoxy-4-carboxymethylbenzoate\n427-630-2\n99469-99-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-582-00-0\nreaction mass of: tetrasodium 7-(4-(4-fluoro-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate;\ntetrasodium 7-(4-(4-hydroxy-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate\n427-650-1\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-583-00-6\n4-amino-3-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-1-naphthalene sulfonic acid\n427-680-5\n188907-52-0\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-584-00-1\ntrisodium 3-[2-acetylamino-4-[4-chloro-6-[4-(2-sulfonatoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino]phenylazo]naphthalene-1,5-disulfonate\n427-710-7\n215612-56-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n607-585-00-7\nstrontium 2-[(2-hydroxy-6-sulfonato-1-naphthyl)azo]naphthalene-1-sulfonate\n427-930-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-586-00-2\ndodecyl 3-amino-4-chlorobenzoate\n428-020-9\n6195-20-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-587-00-8\nethyl cis-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate\n428-030-3\n67914-69-6\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH410\n607-588-00-3\nreaction mass of: 2-ethylhexyl 2,3,4,5-tetrabromobenzoate;\nbis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate\n428-050-2\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-589-00-9\ntetrakis(1,2,2,6,6-pentamethyl-4-piperidyl)-1,2,3,4-butanetetracarboxylate\n428-070-1\n91788-83-9\nSTOT RE 1\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH372**\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH372**\nH302\nH410\n607-590-00-4\nhexadecyl 3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxovaleramido]-4-isopropoxybenzoate\n428-140-1\n210706-50-6\nAquatic Chronic 4\nH413\n—\nH413\n607-591-00-X\nreaction mass of: trisodium 5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-sulfooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate;\ndisodium 3-(4-ethenesulfonylphenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalene-2,7-disulfonate\n428-400-4\n—\nEye Dam.\nH318\nGHS05\nDgr\nH318\n607-592-00-5\ndi(C9-11-alkyl) cyclohexane-1,4-dicarboxylate\n428-870-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-593-00-0\n4-(2-methylacryloyloxy)phenyl 4-allyloxybenzoate\n429-000-2\n159235-16-2\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-594-00-6\nethyl (1S, 5R, 6S)-5-(1-ethylpropoxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate\n429-020-1\n204254-96-6\nSTOT RE 2 *\nSkin Sens. 1\nH373**\nH317\nGHS08\nGHS07\nWng\nH373**\nH317\n607-595-00-1\nN-amidino-N-methylglycine-2-oxopropionate\n429-120-5\n208535-04-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-596-00-7\nethyl 2-(4-phenoxyphenyl)lactate\n429-220-9\n132584-17-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-597-00-2\ntetrasodium 4,4'-bis{]4-[}4-(2-hydroxyethylamino)-6-(4-sulfonatoanilino)-1,3,5-triazin-2-ylamino{]phenylazo[}stilbene-2,2'-disulfonate\n429-230-3\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-598-00-8\ntrisodium 3-amino-4-[4-[4-(2-(2-ethenylsulfonylethoxy)ethylamino)-6-fluoro-1,3,5-triazine-2-ylamino]-2-sulfophenylazo]-5-hydroxynaphthalene-2,7-disulfonate\n429-240-8\n212652-59-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-599-00-3\n1,1-dimethylpropyl 3,5,5-trimethylperoxyhexanoate\n431-610-9\n68860-54-8\nOrg. Perox. D\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH242\nH317\nH400\nH410\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH317\nH410\n607-600-00-7\n(1S, 1'R)-[1-(3', 3'-dimethyl-1'-cyclohexyl)ethoxycarbonyl]methyl propanoate\n431-700-8\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-601-00-2\n1,4-dihydroxy-2,2,6,6-tetramethyl piperidinium-2-hydroxy-1,2,3-propanetricarboxylate\n429-370-5\n220410-74-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-602-00-8\nethyl (3-cyanomethyl-3,4-dihydro-4-oxophthalazin-1-yl)acetate\n429-680-0\n122665-86-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-603-00-3\nlithium sodium 4,4', 4''-(nitrilotris(ethane-2,1-diylimino(6-chloro-1,3,5-triazine-4,2-diyl)imino))tris(5-hydroxy-6-(1-sulfonaphthalene-2-ylazo)-2,7-naphthalene)disulfonate\n429-730-1\n193562-37-7\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-604-00-9\nguanidinium benzoate\n429-820-0\n26739-54-8\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-605-00-4\nmethyl 4-iodo-2-(3-(4-methoxy-6-methyl-1,3,5-triazine-2-yl)ureidosulfonyl)benzoate\n429-890-2\n144550-06-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-606-00-X\n(Z)-2-(2-t-butoxycarbonylamino-4-thiazolyl)pent-2-enoic acid\n430-100-3\n86978-24-7\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-607-00-5\nreaction mass of: calcium bis(C10-14 branched alkyl salicylate);\ncalcium bis(C18-30-alkyl salicylate);\ncalcium C10-14 branched alkylsalicylato-C18-30-alkyl salicylate;\ncalcium bis (C10-14 branched alkyl phenolate);\ncalcium bis (C18-30-alkyl phenolate);\ncalcium C10-14 branched alkylphenolato-C18-30-alkyl phenolate;\nC10-14 branched alkyl phenol;\nC18-30-alkyl phenol\n430-180-1\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-608-00-0\npentapotassium 2-(4-{]5-[}1-(2,5-disulfophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene{]-3-(2-pyrrolidinone-1-yl)-1,3-pentadienyl[}-3-methylcarbamoyl-5-oxopyrazol-1-yl)benzene-1,4-disulfonate\n430-210-1\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-609-00-6\nethyl (3R)-4-cyano-3-hydroxybutanoate\n430-220-6\n141942-85-0\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-610-00-1\ntrisodium 4-hydroxy-6-(sulfonatomethylamino)-5-(2-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2-sulfonate\n430-280-3\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-611-00-7\nmethyl 3-amino-2,2,3-trimethylbutyrate\n431-720-7\n90886-53-6\nSkin Corr. 1B\nAcute Tox. 4 *\nAquatic Chronic 3\nH314\nH302\nH412\nGHS05\nGHS07\nDgr\nH314\nH302\nH412\n607-612-00-2\nreaction mass of: 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonic acid;\nammonium 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonate\n432-190-1\n182176-52-9\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nH302\nH373**\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\n607-613-00-8\nreaction mass of: succinic acid;\nmonopersuccinic acid;\ndipersuccinic acid;\nmonomethyl ester of succinic acid;\nmonomethyl ester of persuccinic acid;\ndimethyl succinate;\nglutaric acid;\nmonoperglutaric acid;\ndiperglutaric acid;\nmonomethyl ester of glutaric acid;\nmonomethyl ester of perglutaric acid;\ndimethyl glutarate;\nadipic acid;\nmonoperadipic acid;\ndiperadipic acid;\nmonomethyl ester of adipic acid;\nmonomethyl ester of peradipic acid;\ndimethyl adipate;\nhydrogen peroxide;\nmethanol;\nwater\n432-790-1\n—\nMuta. 2\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nH341\nH314\nH332\nH312\nH302\nGHS05\nGHS08\nGHS07\nDgr\nH341\nH314\nH332\nH312\nH302\n607-614-00-3\n2-(10-oxo-10H-9-oxa-10-phosphaphenanthren-10-ylmethyl)succinic acid\n426-480-5\n63562-33-4\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n607-615-00-9\nreaction product of thioglycerol and mercaptoacetic acid consisting mainly of 3-mercapto-1,2-bismercaptoacetoxypropane and oligomers of this substance\n431-120-5\n—\nAcute Tox. 3 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nH331\nH302\nH319\nH317\nGHS06\nDgr\nH331\nH302\nH319\nH317\n607-616-00-4\n2,4-dichloro-5-fluorobenzoylchloride\n428-390-1\n86393-34-2\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH335\nH315\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH335\nH315\nH318\nH317\nH412\n607-617-00-X\nbis(2-ethylhexyl)-4,5-epoxycyclohexane-1,2-dicarboxylate\n430-700-5\n10138-36-0\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-618-00-5\nmenadione sodium bisulfite;\n2-naphthalenesulfonic acid, 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-, sodium salt\n204-987-0\n130-37-0\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n607-619-00-0\nmenadione nicotinamide bisulfite;\n1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphthalene-2-sulfonic acid, compound with nicotin-3-amide (1:1)\n277-543-7\n73581-79-0\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH319\nH315\nH400\nH410\nGHS07\nGHS09\nWng\nH319\nH315\nH410\n607-620-00-6\ntrisodium nitrilotriacetate\n225-768-6\n5064-31-3\nCarc. 2\nAcute Tox. 4 *\nEye Irrit. 2\nH351\nH302\nH319\nGHS08\nGHS07\nWng\nH351\nH302\nH319\nCarc. 2; H351: C ≥ 5 %\n607-621-00-1\nmilbemectin (ISO);\n[reaction mass of milbemycin A3 (CAS No 51596-10-2) and milbemycin A4 (CAS No 51596-11-3) (30:70)]\n—\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH332\nH302\nH410\nM=100\n607-622-00-7\n2-ethylhexyl-2-ethylhexanoate\n231-057-1\n7425-14-1\nRepr. 2\nH361d***\nGHS08\nWng\nH361d***\n607-623-00-2\ndiisobutyl phthalate\n201-553-2\n84-69-5\nRepr. 1B\nH360Df\nGHS08\nDgr\nH360Df\nRepr. 1B; H360Df: C ≥ 25 %\nRepr. 2; H361f: 5 % ≤ C < 25 %\n607-624-00-8\nperfluorooctane sulfonic acid;\nheptadecafluorooctane-1-sulfonic acid; [1]\npotassium perfluorooctanesulfonate;\npotassium heptadecafluorooctane-1-sulfonate; [2]\ndiethanolamine perfluorooctane sulfonate; [3]\nammonium perfluorooctane sulfonate;\nammonium heptadecafluorooctanesulfonate; [4]\nlithium perfluorooctane sulfonate;\nlithium heptadecafluorooctanesulfonate [5]\n217-179-8 [1]\n220-527-1 [2]\n274-460-8 [3]\n249-415-0 [4]\n249-644-6 [5]\n1763-23-1 [1]\n2795-39-3 [2]\n70225-14-8 [3]\n29081-56-9 [4]\n29457-72-5 [5]\nCarc. 2\nRepr. 1B\nSTOT RE 1\nAcute Tox. 4 *\nAcute Tox. 4 *\nLact.\nAquatic Chronic 2\nH351\nH360D***\nH372**\nH332\nH302\nH362\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH360D***\nH372**\nH332\nH302\nH362\nH411\n607-625-00-3\nclodinafop-propargyl (ISO)\n—\n105512-06-9\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH317\nH410\nSkin Sens. 1; H317: C ≥ 0,001 %\nM=1\n607-626-00-9\nethyl 1-(2,4-dichlorophenyl)-5-(trichloromethyl)-1H-1,2,4-triazole-3-carboxylate\n401-290-5\n103112-35-2\nCarc. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH350\nH400\nH410\nGHS08\nGHS09\nDgr\nH350\nH410\n607-627-00-4\n[(4S, 5S)-4-benzyl-2-oxo-5-oxazolidinyl]methyl 4-nitrobenzenesulfonate\n416-360-0\n162221-28-5\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-628-00-X\n4-oxo-4-(p-tolyl)butyric acid adduct with 4-ethylmorpholine\n419-240-6\n171054-89-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-629-00-5\n[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl] acetic acid\n419-270-1\n123599-82-6\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-630-00-0\nacrylic acid, 3-(trimethoxysilyl)propyl ester\n419-560-6\n4369-14-6\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 3\nH332\nH314\nH317\nH412\nGHS05\nGHS07\nDgr\nH332\nH314\nH317\nH412\n607-631-00-6\nreaction mass of: 2-(2-((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate;\n(2-(2-hydroxyethoxy)ethyl) oxo(phenyl)acetate\n442-300-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-632-00-1\nN-[3-(2,4-di-(1,1-dimethyl-propyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamide\n420-210-1\n111244-14-5\nAquatic Chronic 4\nH413\n—\nH413\n607-633-00-7\ntrisodium 5-{][}4-chloro-6-(1-naphthylamino)-1,3,5-triazin-2-yl{]amino[}-4-hydroxy-3-[(E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalenedisulfonate\n440-480-2\n341026-59-3\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-634-00-2\n(S)-(–)-2-acetoxypropionylchloride;\n(1S)-2-chloro-1-methyl-2-oxoethyl acetate\n420-610-4\n36394-75-9\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nH302\nH314\nH317\nGHS05\nGHS07\nDgr\nH302\nH314\nH317\n607-635-00-8\ntrisodium N-(3-propionato)-l-aspartate\n422-090-4\n172737-80-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-636-00-3\n1-bromo-2-methylpropyl propionate\n422-900-6\n158894-67-8\nFlam. Liq. 3\nCarc. 2\nSkin Corr. 1B\nSkin Sens. 1\nH226\nH351\nH314\nH317\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH226\nH351\nH314\nH317\n607-637-00-9\ndisodium 8-amino-5-{]4-[}2-(sulfonatoethoxy)sulfonyl{]phenylazo[}naphthalene-2-sulfonate\n423-730-5\n250688-43-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-638-00-4\n2-hydroxybenzoic acid 2-butyloctyl ester\n431-090-3\n190085-41-7\nAquatic Chronic 4\nH413\n—\nH413\n607-639-00-X\n2-(2-oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenyl acetate\n431-770-1\n216698-07-6\nAquatic Chronic 4\nH413\n—\nH413\n607-641-00-0\n2-(formylamino)-3-thiophenecarboxylic acid;\n2-formamido-3-thiophenecarboxylic acid\n431-930-9\n43028-69-9\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n607-642-00-6\n3,6,9-trithiaundecamethylene-1,11-dimethacrylate\n432-210-7\n141631-22-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n607-643-00-1\ndimethyl (2S)-2-hydroxysuccinate\n432-310-0\n617-55-0\nFlam. Liq. 3\nEye Dam. 1\nSkin Sens. 1\nH226\nH318\nH317\nGHS02\nGHS05\nGHS07\nDgr\nH226\nH318\nH317\n607-644-00-7\nmethyl 2,2-dimethyl-6-methylenecyclohexanecarboxylate\n432-350-9\n81752-87-6\nSkin Irrit. 2\nH315\nGHS07\nWng\nH315\n607-645-00-2\ntetrasodium 2-(4-fluoro-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-sulfonatophenylazo)naphthalene-1,7-disulfonate\n432-550-6\n243858-01-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-646-00-8\nd-erythro-hexanoic acid 2,4-dideoxy-3,5-O-(1-methylethylidene)-1,1-dimethylethylester;\ntert-butyl 2-[(4R, 6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate\n432-960-5\n124655-09-0\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-647-00-3\n5-acetoxy-2-(R, S)butyryloxymethyl-1,3-oxathiolane\n433-530-1\n143446-73-5\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nH302\nH317\nH400\nGHS07\nGHS09\nWng\nH302\nH317\nH400\n607-649-00-4\n[3-(chlorocarbonyl)-2-methylphenyl]acetate\n433-690-0\n167678-46-8\nSkin Corr. 1A\nSkin Sens. 1\nH314\nH317\nGHS05\nGHS07\nDgr\nH314\nH317\n607-650-00-X\n2-methyl-1,5-pentanediamine-1,3-benzenedicarboxylate\n433-910-5\n145153-52-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-651-00-5\nsodium 2-(nonanoyloxy)benzenesulfonate\n434-360-9\n91125-43-8\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-652-00-0\nethyl N 2-dodecanoyl-l-argininate hydrochloride\n434-630-6\n60372-77-2\nEye Dam. 1\nAquatic Acute 1\nH318\nH400\nGHS05\nGHS09\nDgr\nH318\nH400\n607-653-00-6\ntetrakis(bis(2-hydroxyethyl)methylammonium) 3-(4-(7-acetylamino-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-5-methoxy-2-sulfonatophenylazo)-7-(4-amino-3-sulfonatophenylamino)-4-hydroxynaphthalene-2-sulfonate\n434-840-8\n225786-91-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-654-00-1\n(S)-3-hydroxy-γ-butyrolactone\n434-990-4\n7331-52-4\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-655-00-7\nethyl 6,8-dichlorooctanoate\n435-080-1\n1070-64-0\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-656-00-2\nsodium salt of 4-amino-3,6-bis[[5-[[4-chloro-6-[(2-methyl-4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-5-hydroxy-2,7-naphthalenedisulfonic acid\n435-350-7\n141250-43-3\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-657-00-8\npentasodium 7-(4-(4-(3-(2-sulfatoethanesulfonyl)phenylamino)-6-(4-(2-sulfatoethanesulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate\n436-920-8\n172399-10-9\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-658-00-3\n3,10-diamino-6,13-dichloro-2-((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazinedisulfonic acid, lithium potassium sodium salt\n440-770-9\n371921-63-0\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-659-00-9\npentasodium N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalen-2-yl)azo]phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[[-2-(oxysulfonato)ethyl] sulfonyl]phenyl]azo]phenyl]-3-aminopropanoic acid\n442-030-0\n321912-47-4\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-660-00-4\n2-{]4-[}4-[4-fluoro-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino{]phenylazophenylazo[}naphthalene-4,6,8-trisulfonate, trisodium salt\n442-230-8\n321679-52-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n607-661-00-X\n1,1-dimethylethyl 4'-(bromomethyl)biphenyl-2-carboxylate\n442-850-9\n114772-40-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-662-00-5\nmethyl 2-(acetylamino)-3-chloropropionate\n442-860-3\n87333-22-0\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n607-663-00-0\nbis(2-ethylhexyl) naphthalene-2,6-dicarboxylate\n442-980-6\n127474-91-3\nAquatic Chronic 4\nH413\n—\nH413\n607-664-00-6\nmethyl 2-chlorosulfonyl-4-(methanesulfonylaminomethyl) benzoate\n443-120-2\n393509-79-0\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-665-00-1\ntrans-methyl-2-ethyl-but-2-enoate\n443-150-6\n101226-85-1\nFlam. Liq. 3\nH226\nGHS02\nWng\nH226\n607-666-00-7\n(2S)-5-(benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid\n443-560-5\n88784-33-2\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n607-667-00-2\nchloro-1-ethylcyclohexyl carbonate\n444-950-8\n99464-83-2\nMuta. 2\nSkin Sens. 1\nH341\nH317\nGHS08\nGHS07\nWng\nH341\nH317\n607-668-00-8\ntrans-2-isopropyl-5-carboxy-1,3-dioxane\n445-770-2\n42031-28-7\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n607-669-00-3\nmethyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl)octadecanoate\n445-990-9\n376588-17-9\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n607-670-00-9\ndibutyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonyl)phenoxy)propyl ammonium oxalate;\n(5-amino-2-butylbenzofuran-3-yl) [4-(3-dibutylaminopropoxy)phenyl]methanone, dioxalate\n448-700-9\n500791-70-8\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH373**\nH318\nH317\nH410\nM=10\n607-671-00-4\ndiethyl 1,4-cyclohexanedicarboxylate\n417-310-0\n72903-27-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n607-672-00-X\nreaction mass of: 2-hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoate;\n1-hydroxymethyl-2-(methacryloyloxy)ethyl (2-benzoyl)benzoate;\nx-hydroxy-y-(methacryloyloxy)propyl(or -ethyl) (2-benzoyl)benzoate\n419-000-0\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-673-00-5\n1-ethyl-5,6,7,8-tetrahydroquinolinium tosylate\n419-570-0\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n607-675-00-6\nreaction mass of: cis-9-octadecenedioic acid;\ncis-9-cis-12-octadecadienedioic acid;\nhexadecanedioic acid;\noctadecanedioic acid\n422-260-8\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n607-676-00-1\nreaction mass of: 2-methylnonanedioic acid;\n2,4-dimethyl-4-methoxycarbonylundecanedioic acid;\n2,4,6-trimethyl-4,6-dimethoxycarbonyltridecanedioic acid;\n8,9-dimethyl-8,9-dimethoxycarbonylhexadecanedioic acid\n423-670-1\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n607-677-00-7\n2,5-dioxopyrrolidin-1-yl N-{][}methyl[[2-(1-methylethyl)-4-thiazolyl{]methylaminocarbonyl[}-l-valinate\n424-660-8\n—\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH373**\nH318\nH317\n607-678-00-2\nreaction mass of: ethyl (2R, 3R)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate;\nethyl (2S, 3S)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate\n427-090-8\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-679-00-8\nreaction mass of: 3-{]5-[}3-(4-{]1,6-dihydro-2-hydroxy-4-methyl-1-[}3-(methylammonio)propyl{]-6-oxo-3-pyridylazo[}benzamido)phenylazo{]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl[}propyl(methyl)ammonium di(acetate);\n3-{]5-[}4-(3-{]1,6-dihydro-2-hydroxy-4-methyl-1-[}3-(methylammonio)propyl{]-6-oxo-3-pyridylazo[}benzamido{]phenylazo-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl[}propyl(dimethyl)ammonium di(acetate);\n3-{]5-[}3-(4-{]1-[}3-(dimethylammonio)propyl{]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo[}benzamido)phenylazo{]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl[}propyl(dimethyl)ammonium di(acetate)\n431-440-5\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n607-680-00-3\ntert-butyl(6-{]2-[}4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino{]pyrimidin-5-ylvinyl[}(4S, 6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate\n432-810-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-681-00-9\nreaction mass of: 9-nonyl-10-octyl-19-carbonyloxyhexadecylnonadecanoic acid;\n9-nonyl-10-octyl-19-carbonyloxyoctadecylnonadecanoic acid;\ndihexadecyl 9-nonyl-10-octylnonadecandioate;\n1-octadecyl, 19-hexadecyl 9-nonyl-10-octylnonadecandioate;\ndioctadecyl 9-nonyl-10-octylnonadecandioate\n432-910-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-682-00-4\ncomplex reaction mass of Chinese gum rosin post reacted with acrylic acid\n434-230-1\n144413-22-9\nAquatic Chronic 4\nH413\n—\nH413\n607-683-00-X\nreaction mass of: methyl 3-((1E)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate;\nmethyl 3-((1Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80)\n435-450-0\n—\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n607-684-00-5\nalkenes, C12-14, hydroformylation products, distn. residues, C-(hydrogen sulfobutanedioates), disodium salts\n435-660-2\n243662-67-1\nSkin Irrit. 2\nSkin Sens. 1\nH315\nH317\nGHS07\nWng\nH315\nH317\n607-685-00-0\nammonium 2-cocoyloxyethanesulfonate\n441-050-7\n—\nSkin Irrit. 2\nEye Dam. 1\nH315\nH318\nGHS05\nDgr\nH315\nH318\n607-686-00-6\n6,6'-bis(diazo-5,5', 6,6'-tetrahydro-5,5'-dioxo)[methylene-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulphonyloxy)-6-methyl-2-phenylene]di(naphthalene-1-sulfonate)\n441-550-5\n—\nSelf-react. C ****\nCarc. 2\nH242\nH351\nGHS02\nGHS08\nDgr\nH242\nH351\n607-687-00-1\nreaction mass of: 2-{]3,6-bis-[}(2-ethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (2-10 %);\n2-{]3,6-bis-[}(2,3-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (2-10 %);\n2-{]3,6-bis-[}(2,4-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (2-10 %);\n2-{]3,6-bis-[}(2,5-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (2-10 %);\n2-{]3-[}(2,3-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %);\n2-{]3-[}(2,4-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %);\n2-{]3-[}(2,5-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %);\n2-{]3-[}(2,3-dimethylphenyl)-methylamino]-6-[(2,4-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %);\n2-{]3-[}(2,3-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %);\n2-{]3-[}(2,4-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino{]-xanthylium-9-yl[}-benzenesulfonate (7-20 %)\n442-800-6\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n607-688-00-7\n(R)-1-cyclohexa-1,4-dienyl-1-methoxycarbonyl-methylammoniumchloride\n444-320-2\n—\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n607-689-00-2\nreaction mass of: methyl 1,4-dimethylcyclohexanecarboxylate (‘para-isomer’ including cis- and trans- isomers);\nmethyl 1,3-dimethylcyclohexanecarboxylate (‘meta-isomer’ including cis- and trans-isomers)\n444-920-4\n—\nAquatic Chronic 3\nH412\n—\nH412\n607-690-00-8\ndimethyl[2S, 2S']-6,6,6'6'-tetramethoxy-2,2'-[N,N'-bis(trifluoracetyl)-S, S'-bi(L-homocysteinyl) diimino]dihexanoate\n432-860-1\n255387-46-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n607-691-00-3\nmagnesium salts, fatty acids, C16-18 and C18 unsaturated, branched and linear\n448-690-6\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-692-00-9\nzinc salts, fatty acids, C16-18 and C18 unsaturated, branched and linear\n446-470-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n607-693-00-4\nhexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl)benzoate\n443-860-6\n302776-68-7\nAquatic Chronic 4\nH413\n—\nH413\n607-694-00-X\nethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate\n443-870-0\n163520-33-0\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n608-020-00-7\ndiphenoxymethylenecyanamide\n427-300-8\n79463-77-7\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n608-032-00-2\nacetamiprid (ISO);\n(E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine\n—\n135410-20-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n608-042-00-7\n(S)-2,2-diphenyl-2-(3-pyrrolidinyl)acetonitrile hydrobromide\n421-810-4\n194602-27-2\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n608-044-00-8\n2-cyclohexylidene-2-phenylacetonitrile\n423-740-1\n10461-98-0\nAcute Tox. 4 *\nAquatic Chronic 2\nH302\nH411\nGHS07\nGHS09\nWng\nH302\nH411\n608-046-00-9\n5-(4-chloro-2-nitro-phenylazo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-pyridine-3-carbonitrile\n425-310-7\n77889-90-8\nAquatic Chronic 4\nH413\n—\nH413\n608-047-00-4\n2-piperidin-1-yl-benzonitrile\n427-330-1\n72752-52-4\nAquatic Chronic 2\nH411\nGHS09\nH411\n608-048-00-X\n1-(3-cyclopentyloxy-4-methoxyphenyl)-4-oxo-cyclohexanecarbonitrile\n427-450-4\n152630-47-2\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH373**\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH317\nH411\n608-049-00-5\n2-(4-(4-(butyl-(1-methylhexyl)amino)phenyl)-3-cyano-5-oxo-1,5-dihydropyrrol-2-ylidene)propandinitrile\n429-180-2\n157362-53-3\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n608-050-00-0\nreaction mass of: 5-(2-cyano-4-nitrophenylazo)-2-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-6-phenylaminonicotinonitrile;\n5-(2-cyano-4-nitrophenylazo)-6-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-2-phenylaminonicotinonitrile\n429-760-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n608-051-00-6\n(R)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-760-2\n219861-18-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-052-00-1\n(S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-770-7\n128173-52-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-053-00-7\n(R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile\n430-780-1\n103146-25-4\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n608-054-00-2\n(R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile hemisulfate\n430-790-6\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH317\nH411\n608-055-00-8\nfipronil (ISO);\n5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile\n—\n120068-37-3\nAcute Tox. 3 *\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH311\nH301\nH372**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH301\nH372**\nH410\nM=10\n608-056-00-3\nN-methyl-N-cyanomethylmorpholiniummethylsulfate\n429-340-1\n—\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n608-057-00-9\n4-cyanomethyl-4-methylmorpholin-4-iumhydrogene sulfate\n431-200-1\n208538-34-5\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH318\nH317\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\n608-059-00-X\n5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile\n421-240-6\n120068-79-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n608-060-00-5\n5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile\n421-300-1\n138564-59-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n608-062-00-6\n2-fluoro-4-hydroxybenzonitrile\n422-810-7\n82380-18-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n608-063-00-1\n(S)-α-hydroxy-3-phenoxy-benzeneacetonitrile\n441-070-6\n61826-76-4\nAcute Tox. 3 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH301\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH301\nH318\nH317\nH410\n608-064-00-7\ncyanomethyltrimethylammoniummethylsulfate\n433-720-2\n—\nAquatic Chronic 3\nH412\n—\nH412\n609-069-00-7\nmusk ketone;\n3,5-dinitro-2,6-dimethyl-4-tert-butylacetophenone;\n4'-tert-butyl-2', 6'-dimethyl-3', 5'-dinitroacetophenone\n201-328-9\n81-14-1\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n609-072-00-3\n4-mesyl-2-nitrotoluene\n430-550-0\n1671-49-4\nRepr. 2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH361f***\nH302\nH317\nH412\nGHS08\nGHS07\nDgr\nH361f***\nH302\nH317\nH412\n609-073-00-9\nlithium potassium sodium N,N''-bis{]6-[}7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo){]naphthalene-1,3,6-trisulfonato[}-N'-(2-aminoethyl)piperazine\n427-850-9\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n611-050-00-3\nreaction mass of: pentasodium 7-amino-3-[[4-[[4-[[4-[[4-[(6-amino-1-hydroxy-3-sulfonato-2-naphthyl)azo]-7-sulfonato-1-naphthyl]azo]phenyl]amino]-3-sulfonatophenyl]azo]-6-sulfonato-1-naphthyl]azo]-4-hydroxynaphthalen-2-sulfonate;\npentasodium 7-amino-8-[4-[4-[4-[4-(2-amino-5-hydroxy-7-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate;\npentasodium 7-amino-8-[4-[4-[4-[4-(6-amino-1-hydroxy-3-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate;\ntetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-hydroxy-7-sulfonato-naphthalen-1-ylazo)-2-sulfonato-phenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate;\ntetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-amino-7-sulfonato-naphthalen-1-ylazo)-2-sulfonato-phenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate\n415-350-3\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-102-00-5\nreaction product of: C.I. Leuco Sulfur Black 1 and reaction mass of: disodium-4-{]4-[}8-amino-1-hydroxy-7-(4-sulfamoylphenylazo)-3,6-disulfonato-2-naphthylazo{]phenylsulfonylamino[}benzendiazoniumchlorid;\ndisodium-4-{]4-[}2,6-dihydroxy-3-(8-hydroxy-3,6-disulfonato-1-naphthylazo)phenylazo{]phenylsulfonylamino[}benzen-diazoniumchlorid\n424-500-7\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-139-00-7\nreaction product of: C.I. Leuco Sulfur Black 1 with (3-chloro-2-hydroxypropyl)trimethylammonium chloride\n424-510-1\n—\nEye Dam. 1\nAquatic Chronic 2\nH318\nH411\nGHS05\nGHS09\nDgr\nH318\nH411\n611-141-00-8\n5-(4-[4-[4-(3,5-dicarboxy-phenyl-azo)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]phenylazo)isophthalic acid, mixed monosodium and diammonium salt\n414-410-6\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-142-00-3\nproduct-by-process definition polyazodyestuff obtained by coupling 4-[4-(1-amino-8-hydroxy-3,6-disulfo-2-naphthylazo)phenylsulfonylamino]benzenediazonium with reaction mass of 4-carboxybenzenediazonium and diphenylamine-3-sulfo-4,4'-bisdiazonium, and further coupling of the obtained compounds with reaction mass of naphth-2-ol and 3-aminophenol, sodium salts;\nsodium chloride\n425-740-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-143-00-9\nreaction mass of: trisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(2,6-difluoropyrimidin-4-ylamino)-4-sulfonatophenolatocuprate (II);\ntrisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(4,6-difluoropyrimidin-2-ylamino)-4-sulfonatophenolatocuprate (II)\n428-260-4\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-144-00-4\nreaction mass of: 7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt;\n7-amino-3-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxy-8-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt;\n7-amino-8-[4-(2-sulfoxyethylsulfonyl)-phenylazo]-4-hydroxy-3-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt;\n7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt\n429-070-4\n214362-06-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-145-00-X\nreaction mass of: tetrasodium 3-(1,5-disulfonatonaphthalene-2-ylazo)-4-hydroxy-7-{]4-chloro-6-[}4-(2-sulfoxyethylsulfonyl)phenylamino{]-1,3,5-triazine-2-ylamino[}naphthalene-2-sulfonate;\n3-(2,5-disulfophenylazo)-4-hydroxy-7-{]4-chloro-6-[}4-(2-sulfoxyethylsulfonyl)phenylamino{]-1,3,5-triazine-2-ylamino[}naphthalene-2-sulfonic acid, sodium salt\n429-440-5\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-146-00-5\nreaction mass of: pentasodium 3-(4-(4-(7-(2,4-diamino-5-sulfonato-3-(4-sulfonatophenylazo)phenylazo)-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-2-sulfonatophenylamino)phenylazo)-4-hydroxy-6-(2-oxo-1-phenylcarbamoylpropylazo)naphthalene-2-sulfonate;\npentasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonatophenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)phenyl)amino)-2-sulfonatophenyl)azo)-4-hydroxynaphthalene-2-sulfonate;\npentasodium 6-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-3-((4-((4-((1,7-dihydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate;\nhexasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate\n430-070-1\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-147-00-0\nsodium, potassium, lithium 5-amino-3,6-bis(5-(4-chloro-6-(methyl-(2-methylaminoacetyl)amino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-4-hydroxynaphthalene-2,7-disulfonate\n430-090-0\n205764-96-1\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-148-00-6\nreaction mass of: 2-(3-(2,6-dichloro-4-nitrophenylazo)carbazol-9-yl)ethanol;\n2-(2-(3-(2,6-dichloro-4-nitro-phenylazo)-carbazol-9-yl)-ethoxy)ethanol;\n3-(2,6-dichloro-4-nitrophenylazo)carbazol\n429-590-1\n—\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n611-149-00-1\n2-(2-chloroacetoxy)ethyl 3-((4-(2,5-dichloro-4-fluorosulfonylphenylazo)-3-methylphenyl)ethylamino)propionate\n427-570-7\n193486-83-8\nAquatic Chronic 2\nH411\nGHS09\nH411\n611-150-00-7\ntetralithium 2-[6-[7-[2-(carboxylato)phenylazo]-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazine-2-ylamino]benzoate\n440-460-3\n—\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n611-151-00-2\nchrysoidine;\n4-(phenylazo)benzene-1,3-diamine\n207-803-7\n495-54-5\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH315\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH302\nH315\nH410\n611-152-00-8\nchrysoidine monohydrochloride;\n4-phenylazophenylene-1,3-diamine monohydrochloride; [1]\nchrysoidine monoacetate;\n4-(phenylazo)benzene-1,3-diamine monoacetate; [2]\nchrysoidine acetate;\n4-(phenylazo)benzene-1,3-diamine acetate; [3]\nchrysoidine-p-dodecylbenzenesulfonate;\ndodecylbenzenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1); [4]\nchrysoidine dihydrochloride;\n4-(phenylazo)benzene-1,3-diamine dihydrochloride; [5]\nchrysoidine sulfate;\nbis[4-(phenylazo)benzene-1,3-diamine] sulfate [6]\n208-545-8 [1]\n278-290-5 [2]\n279-116-0 [3]\n264-409-8 [4]\n281-549-5 [5]\n282-432-1 [6]\n532-82-1 [1]\n75660-25-2 [2]\n79234-33-6 [3]\n63681-54-9 [4]\n83968-67-6 [5]\n84196-22-5 [6]\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH315\nH318\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH341\nH302\nH315\nH318\nH410\n611-153-00-3\nchrysoidine C10-14-alkyl derivatives;\nbenzenesulfonic acid, mono-C10-14-alkyl derivatives, compounds with 4-(phenylazo)-1,3-benzenediamine; [1]\nchrysoidine compound with dibutylnaphthalene sulfonic acid;\ndibutylnaphthalenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1) [2]\n286-946-7 [1]\n304-236-8 [2]\n85407-90-5 [1]\n94247-67-3 [2]\nMuta. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nH341\nH302\nH315\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH341\nH302\nH315\nH318\n611-154-00-9\ntrisodium 5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalene-2,7-disulfonate\n403-670-6\n92408-46-3\nAquatic Chronic 3\nH412\n—\nH412\n611-155-00-4\n4,4'-oxybis(benzenesulfonylazide)\n431-850-4\n7456-68-0\nExpl. 1.1****\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH201\nH373**\nH400\nH410\nGHS01\nGHS08\nGHS09\nDgr\nH201\nH373**\nH410\n611-156-00-X\ntriammonium 4-[4-[7-(4-carboxylatoanilino)-1-hydroxy-3-sulfonato-2-naphthylazo]-2,5-dimethoxyphenylazo]benzoate\n432-270-4\n221354-37-6\nRepr. 2\nSTOT RE 2 *\nAquatic Chronic 2\nH361f***\nH373**\nH411\nGHS08\nGHS09\nWng\nH361f***\nH373**\nH411\n611-157-00-5\nbenzenesulfonic acid, 3,3'-(methylenebis((dihydroxyphenylene)azo))bis-, potassium sodium salt;\npotassium sodium 3-[(E)-(6-{]3,4-dihydroxy-2-[}(Z)-(3-sulfonatophenyl)diazenyl{]benzyl[}-2,3-dihydroxyphenyl)diazenyl]benzenesulfonate\n432-590-4\n243869-48-9\nEye Irrit. 2\nAquatic Chronic 3\nH319\nH412\nGHS07\nWng\nH319\nH412\n611-158-00-0\nreaction product of: 2,3,4,2', 3', 4'-hexahydroxy-5,5'-diacethyl-diphenylmethane and 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonylchloride and 3-diazo-3,4-dihydro-6-methoxy-4-oxo-1-naphthalenesulfonylchloride\n421-520-8\n—\n****\nAquatic Chronic 4\n****\nH413\n****\n****\nH413\n611-159-00-6\ndisodium 4-amino-6-((4-((4-(2,4-diaminophenyl)azo)phenylsulfamoyl)phenyl)azo)-5-hydroxy-3-((4-nitrophenyl)azo)naphthalene-2,7-disulfonate\n421-880-6\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-160-00-1\nreaction mass of: 1,1,1-tris(phenyl-4'-(3''-diazo-3'', 4''-dihydro-4''-oxo-naphthalene-1''-sulfonato)ethane;\n1,1,1-tris(phenyl-4'-(6''-diazo-5'', 6''-dihydro-5''-oxo-naphthalene-1''-sulfonato)ethane;\nreaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (2:1);\nreaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (1:2)\n422-760-6\n—\n****\nAquatic Chronic 4\n****\nH413\n****\n****\nH413\n611-161-00-7\ntrisodium [1,2'-(2-(8-amino-3,5-disulfonatonaphthalene)azo)-(4'-nitrobenzene)diolato-O,O,N][(Z)-2,2-((phenylcarbamoylprop-1'-enyl)azo)-5-sulfamoylbenzene)diolato-O,O,N]chromate(III)\n423-100-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-162-00-2\n2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diolbis(methanesulfonate)\n429-600-4\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n611-163-00-8\n2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diol sulfate\n429-610-9\n—\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 2\nH302\nH318\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH411\n611-164-00-3\nreaction mass of: 2,2'-dimethyl-2,2'-azobutanenitrile;\n2-methylpentanenitrile-2-azo-2'-(2'-methylpropanenitrile);\n2,2'-dimethyl-2,2'-azoheptanenitrile;\n2-methylheptanenitrile-2-azo-2'-(2'-methylpropanenitrile);\n2-methylheptanenitrile-2-azo-2'-(2'-methylbutanenitrile)\n429-710-2\n—\nSelf React D\nAcute Tox. 4 *\nAquatic Chronic 2\nH242\nH302\nH411\nGHS02\nGHS07\nGHS09\nDgr\nH242\nH302\nH411\n611-165-00-9\nreaction mass of: tetrasodium 4-amino-6-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-6-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate\n431-830-5\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-166-00-4\nreaction mass of: pentasodium 4-amino-5-hydroxy-3-{](E)-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-6-{](E)-2-sulfonato-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-3-{](E)-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo{]naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-6-(E)-2-sulfonato-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate\n432-100-9\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-167-00-X\nsodium bis[tris(2-hydroxyethyl)ammonium][6-anilino-4'-(4,8-disulfonato-2-naphthylazo)-5'-methyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cuprate(II)\n435-240-9\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-168-00-5\nreaction mass of: 3-[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chloro-6-[[8-hydroxy-3,6-disulfo-7-[(2-sulfophenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid;\n3,5-bis[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid\n435-440-6\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-169-00-0\nsodium 5-(2-carboxyphenylazo)-6-hydroxynaphthalene-2-sulfonate\n435-800-2\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-170-00-6\nreaction mass of: trisodium 2-((1-(2-hydroxy-κ-O-5-(2-sulfonatoethansulfonyl)phenylazo-κ-N2 )-1-phenylmethyl)azo-κ-N1 )-4-sulfonatobenzoate(5-)-κ-O)cuprate(II);\ndisodium 2-((1-(5-ethenesulfonyl-2-hydroxy-κ-O-phenylazo-κ-N2 )-1-phenylmethyl)azo-κ-N1 )-4-sulfonatobenzoate-κ-O-(5-))cuprate(II)\n435-880-9\n—\nAquatic Chronic 3\nH412\n—\nH412\n611-171-00-1\nreaction mass of: trisodium 3-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate;\ntrisodium 3-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate\n436-890-6\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-172-00-7\nreaction mass of: triammonium 6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate;\ndiammonium 3-((4-((7-amino-1-hydroxy-3-sulfo-naphthalen-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoate\n438-310-7\n—\nSelf-react. C****\nRepr. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH242\nH361f***\nH302\nH373**\nH412\nGHS02\nGHS08\nGHS07\nDgr\nH242\nH361f***\nH302\nH373**\nH412\n611-173-00-2\nreaction mass of: 3-[3-carbamoyl-5-(5-{]4-chloro-6-[}4-(2-sulfonatooxyethylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, trisodium salt;\n3-[3-carbamoyl-5-(5-{]4-chloro-6-[}4-(vinylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, disodium salt\n440-510-4\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-174-00-8\nreaction mass of: 3-[5-(4-ethenesulfonylbutyrylamino)-2-sulfophenylazo{]-5-4-chloro-[}6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino{]-1,3,5-triazin-2-ylamino[}-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt;\n3-[5-(4-(2-chloroethanesulfonyl)butyrylamino)-2-sulfophenylazo{]-5-4-chloro-[}6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino{]-1,3,5-triazin-2-ylamino[}-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt\n442-290-5\n457624-86-1\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n611-175-00-3\nreaction mass of: trisodium 5-{]4-chloro-6-[}N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo{]naphthalene-2,7-disulfonate;\ntrisodium 5-4-chloro-6-[}N-ethyl-3-(vinylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo{]naphthalene-2,7-disulfonate;\ndisodium 5-4-chloro-6-[}N-ethyl-3-(vinylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-4-hydroxy-3-[(4-vinylsulfonyl)phenylazo{]naphthalene-2,7-disulfonate;\ntetrasodium 5-4-chloro-6-[}N-ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino{]-1,3,5-triazin-2-ylamino[}-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2,7-disulfonate\n444-050-5\n—\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n611-176-00-9\n2,6-bis(2,3,4-trihydroxybenzyl)-p-cresol ester with 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonate\n444-250-2\n—\nSelf-react. C****\nAquatic Chronic 2\nH242\nH411\nGHS02\nGHS09\nDgr\nH242\nH411\n611-177-00-4\nreaction mass of: pentasodium bis[6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III);\ntetrasodium [6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato][6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III);\ntrisodium bis[6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III)\n444-290-0\n508202-43-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n611-178-00-X\nreaction mass of: pentasodium 4-amino-5-hydroxy-3-{](E)-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-6-{](E)-2-sulfonato-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-3-{](E)-4-[}2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntetrasodium 4-amino-5-hydroxy-6-[(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl{]phenylazo[}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntrisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntrisodium 4-amino-5-hydroxy-3-[(2-hydroxyethylsulfonyl)-phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate;\ntrisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[-2-sulfonato-4-(2-hydroxyethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate\n445-280-9\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n611-179-00-5\nreaction mass of: pentasodium 2-[[8-[[4-chloro-6-[[4-(2-sulfonato ethylsulfonyl)]phenyl]amino]-1,3,5-triazin-2-yl]amino-1- hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate;\n2-[[8-[[4-chloro-6-[[4-[[2-ethenyl]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate\n450-010-8\n—\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n611-180-00-0\niron, complexes with diazotised 4-aminobenzenesulfonamide, diazotised 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts\n417-850-7\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-057-01-1\npiperazine;\n[liquid]\n203-808-3\n110-85-0\nRepr. 2\nSkin Corr. 1B\nResp. Sens. 1\nSkin Sens. 1\nH361fd\nH314\nH334\nH317\nGHS05\nGHS08\nDgr\nH361fd\nH314\nH334\nH317\n612-122-01-4\nhydroxylamine …% [≤ 55 % in aqueous solution]\n232-259-2\n7803-49-8\nMet. Corr. 1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH290\nH351\nH312\nH302\nH373**\nH335\nH315\nH318\nH317\nH400\nB\n612-169-00-3\nbis(N-methyl-N-phenylhydrazine)sulfate\n423-170-1\n618-26-8\nFlam. Liq. 2\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH372**\nH302\nH318\nH317\nH400\nH410\nGHS02\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH225\nH372**\nH302\nH318\nH317\nH410\n612-203-00-7\nC8-10 alkyl dimethyl hydroxyethyl ammoniumchloride (chain < C8: <3 %, chain= C8: 15 %-70 %, chain= C10: 30 %-85 %, chain > C10: <3 %)\n417-360-3\n—\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nH312\nH302\nH315\nGHS07\nWng\nH312\nH302\nH315\n612-208-00-4\nN-methylbenzene-1,2-diammonium hydrogen phosphate\n424-460-0\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n612-216-00-8\n1-amino-1-cyanamino-2,2-dicyanoethylene, sodium salt\n425-870-2\n19450-38-5\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n612-219-00-4\n(2-hydroxy-3-(3,4-dimethyl-9-oxo-10-thiaanthracen-2-yloxy)propyl)trimethylammonium chloride\n402-200-7\n—\nAquatic Chronic 3\nH412\n—\nH412\n612-220-00-X\nN-nitro-N-(3-methyl-3,6-dihydro-2H-1,3,5-oxadiazin-4-yl)amine\n431-060-1\n153719-38-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n612-221-00-5\n2-amino-4-(trifluoromethyl)benzenethiol hydrochloride\n429-560-8\n4274-38-8\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nH314\nH332\nH312\nH302\nH373**\nH317\nH400\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH314\nH332\nH312\nH302\nH373**\nH317\nH400\n612-222-00-0\ncis-1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinamine\n425-080-8\n104860-26-6\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH312\nH302\nH373**\nH318\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH312\nH302\nH373**\nH318\nH410\n612-223-00-6\nN-benzyl-N-ethyl-(4-(5-nitro-benzo[c]isothiazol-3-ylazo)phenyl)amine\n425-300-2\n186450-73-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n612-224-00-1\nN2,N4,N6-tris{]4-[}(1,4-dimethylpentyl)amino{]phenyl[}-1,3,5-triazine-2,4,6-triamine\n426-150-0\n121246-28-4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n612-225-00-7\n1,4,7,10-tetraazacyclododecane\n425-450-9\n294-90-6\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH312\nH302\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH312\nH302\nH410\n612-226-00-2\n3-(2'-phenoxyethoxy)propylamine\n427-870-8\n6903-18-0\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH302\nH315\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH315\nH318\nH412\n612-227-00-8\nbenzyl-N-(2-(2-methoxyphenoxy)ethyl)amine hydrochloride\n428-290-8\n120606-08-8\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n612-228-00-3\nreaction mass of: N-(3-(trimethoxysilyl)propyl)ethylenediamine;\nN-benzyl-N-(3-(trimethoxysilyl)propyl)ethylenediamine;\nN-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine;\nN,N'-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine;\nN,N,N'-tris-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine;\nN,N-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine\n414-340-6\n—\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT SE 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH226\nH332\nH312\nH302\nH371\nH318\nH317\nH412\nGHS02\nGHS05\nGHS08\nGHS07\nDgr\nH226\nH332\nH312\nH302\nH371\nH318\nH317\nH412\n612-229-00-9\nmepanipyrim;\n4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine\n—\n110235-47-7\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\n612-230-00-4\nN,N-bis(cocoyl-2-oxypropyl)-N,N-dibutylammonium bromide\n431-530-4\n—\nSkin Corr. 1A\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH317\nH410\n612-231-00-X\n3-((C12-18)-acylamino)-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl-1-propanaminium chloride\n427-370-1\n164288-56-6\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n612-232-00-5\nreaction mass of: triisopropanolamine salt of 1-amino-4-(3-propionamidoanilino)anthraquinone-2-sulfonic acid;\ntriisopropanolamine salt of 1-amino-4-[3,4-dimethyl-5-(2-hydroxyethylaminosulfonyl)anilino]anthraquinone-2-sulfonic acid\n430-410-9\n186148-38-9\nAquatic Chronic 3\nH412\n—\nH412\n612-237-00-2\nhydroxylammonium hydrogensulfate;\nhydroxylamine sulfate(1:1); [1]\nhydroxylamine phosphate; [2]\nhydroxylamine dihydrogenphosphate; [3]\nhydroxylamine 4-methylbenzenesulfonate [4]\n233-154-4 [1]\n244-077-0 [2]\n242-818-2 [3]\n258-872-5 [4]\n10046-00-1 [1]\n20845-01-6 [2]\n19098-16-9 [3]\n53933-48-5 [4]\nExpl. 1.1\nCarc. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH201\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\nHS01\nGHS08\nGHS07\nGHS09\nDgr\nH201\nH351\nH312\nH302\nH373**\nH319\nH315\nH317\nH400\nT\n612-238-00-8\n(3-chloro-2-hydroxypropyl) trimethylammonium chloride …%\n222-048-3\n3327-22-8\nCarc. 2\nAquatic Chronic 3\nH351\nH412\nGHS08\nWng\nH351\nH412\nB\n612-239-00-3\nbiphenyl-3,3', 4,4'-tetrayltetraamine;\ndiaminobenzidine\n202-110-6\n91-95-2\nCarc. 1B\nMuta. 2\nH350\nH341\nGHS08\nDgr\nH350\nH341\n612-240-00-9\npyrimethanil (ISO);\nN-(4,6-dimethylpyrimidin-2-yl)aniline\n—\n53112-28-0\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-241-00-4\npiperazine hydrochloride; [1]\npiperazine dihydrochloride; [2]\npiperazine phosphate [3]\n228-042-7 [1]\n205-551-2 [2]\n217-775-8 [3]\n6094-40-2 [1]\n142-64-3 [2]\n1951-97-9 [3]\nRepr. 2\nEye Irrit. 2\nSkin Irrit. 2\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 3\nH361fd\nH319\nH315\nH334\nH317\nH412\nGHS08\nDgr\nH361fd\nH319\nH315\nH334\nH317\nH412\n612-242-00-X\ncyprodinil (ISO);\n4-cyclopropyl-6-methyl-N-phenylpyrimidin-2-amine\n—\n121552-61-2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n612-243-00-5\n(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine 2-hydroxy-2-phenylacetate\n420-560-3\n79617-97-3\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\nM=10\n612-244-00-0\n3-(piperazin-1-yl)-benzo[d]isothiazole hydrochloride\n421-310-6\n87691-88-1\nRepr. 2\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f***\nH302\nH319\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361f***\nH302\nH319\nH317\nH410\n612-245-00-6\n2-ethylphenylhydrazine hydrochloride\n421-460-2\n19398-06-2\nCarc. 2\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH372**\nH302\nH318\nH317\nH400\nH410\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH372**\nH302\nH318\nH317\nH410\nM=10\n612-246-00-1\n(2-chloroethyl)(3-hydroxypropyl)ammonium chloride\n429-740-6\n40722-80-3\nCarc. 1B\nMuta. 1B\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH340\nH373**\nH317\nH412\nGHS08\nGHS07\nDgr\nH350\nH340\nH373**\nH317\nH412\n612-247-00-7\nN-[3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-hydroxy-4-nitrobenzenecarboximidamide\n423-530-8\n152828-23-4\nSTOT RE 1\nAcute Tox. 4 *\nAquatic Chronic 3\nH372**\nH302\nH412\nGHS08\nGHS07\nDgr\nH372**\nH302\nH412\n612-248-00-2\nreaction product of diphenylamine, phenothiazine, and alkenes, branched (C8-10, C9-rich)\n439-540-0\n—\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 4\nH315\nH317\nH413\nGHS07\nWng\nH315\nH317\nH413\n612-249-00-8\n4-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride\n425-030-5\n159939-85-2\nRepr. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH361f***\nH302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH361f***\nH302\nH314\nH317\nH411\n612-250-00-3\nchloro-N,N-dimethylformiminium chloride\n425-970-6\n3724-43-4\nRepr. 1B\nAcute Tox. 4 *\nSkin Corr. 1A\nH360D***\nH302\nH314\nGHS05\nGHS08\nGHS07\nDgr\nH360D***\nH302\nH314\nEUH014\n612-251-00-9\ncis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride\n426-020-3\n51229-78-8\nFlam. Sol. 2\nRepr. 2\nAcute Tox. 4 *\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH228\nH361d***\nH302\nH315\nH317\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nWng\nH228\nH361d***\nH302\nH315\nH317\nH411\n612-252-00-4\nimidacloprid (ISO);\n1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine\n428-040-8\n138261-41-3\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n612-253-00-X\n7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one;\n[containing < 0,5 % formamide (EC No 200-842-0)]\n429-400-7\n199327-61-2\nAquatic Chronic 3\nH412\n—\nH412\n612-253-01-7\n7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one;\n[containing ≥ 0,5 % formamide (EC No 200-842-0)]\n429-400-7\n199327-61-2\nRepr. 1B\nAquatic Chronic 3\nH360D***\nH412\nGHS08\nDgr\nH360D***\nH412\n612-254-00-5\nreaction products of diisopropanolamine with formaldehyde (1:4)\n432-440-8\n220444-73-5\nCarc. 2\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH351\nH302\nH314\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH351\nH302\nH314\nH317\nH411\n612-255-00-0\n1-(3-methoxypropyl)-4-piperidinamine\n431-950-8\n179474-79-4\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Corr. 1B\nAquatic Chronic 3\nH312\nH302\nH314\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH314\nH412\n612-256-00-6\nbenzyl(S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrate\n427-470-3\n137864-22-3\nAcute Tox. 4 *\nSkin Sens. 1\nH302\nH317\nGHS07\nWng\nH302\nH317\n612-257-00-1\ntripropylammonium dihydrogenphosphate\n433-700-3\n35687-90-2\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n612-259-00-2\nN-ethyl-3-trimethoxysilyl-2-methyl-propanamine\n437-720-3\n227085-51-0\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n612-261-00-3\n3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)aniline\n441-190-9\n121451-05-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=10\n612-265-00-5\nbis(2-hydroxyethyl)-(2-hydroxypropyl)ammonium acetate\n444-360-0\n191617-13-7\nAquatic Chronic 3\nH412\n—\nH412\n612-266-00-0\n3-chloro-4-(3-fluorobenzyloxy)aniline\n445-590-4\n202197-26-0\nMuta. 2\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH341\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH341\nH302\nH373**\nH410\n612-267-00-6\nbis(hydrogenated tallow C16-18-alkyl)hydroxylamine\n418-370-0\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n612-269-00-7\nreaction mass of: 1-[di(4-octylphenyl)aminomethyl]-5-methyl-1H-benzotriazole;\n1-[di(4-octylphenyl)aminomethyl]-4-methyl-1H-benzotriazole;\nreaction mass of: N-[(5-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline;\nN-[(4-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline\n420-720-2\n—\nAquatic Chronic 4\nH413\n—\nH413\n612-270-00-2\n(S)-azetidine-2-carboxylic acid 4-cyanobenzylamide hydrochloride\n433-010-2\n—\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH317\nH412\nGHS07\nWng\nH302\nH317\nH412\n612-271-00-8\nreaction mass of: ethyl 2-((4-(5,6-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate;\nethyl 2-((4-(6,7-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate\n434-970-5\n160987-57-5\nAquatic Chronic 4\nH413\n—\nH413\n612-272-00-3\nammonium (η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butane-1,4-dioato(4-))iron(3+) monohydrate\n435-210-5\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n612-273-00-9\nalkyl(rapeseed oil), bis(2-hydroxyethyl)ammonium fluoride\n435-650-8\n—\nAcute Tox. 4 *\nSkin Corr. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH314\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH314\nH410\n612-274-00-4\n(R, S)-1-[2-amino-1(4-methoxyphenyl)ethyl]cyclohexanol acetate\n445-750-3\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n612-275-00-X\nfatty acids, C18-unsatd., dimers, reaction products with 1-piperazineethanamine and tall oil\n447-880-6\n206565-89-1\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH315\nH318\nH317\nH410\nM=10\n612-276-00-5\n1-amino-4-[(4-amino-2-sulfofenyl)amino]-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, disodium salt, reaction products with 2-[[3-[(4,6-dichloro-1,3,5-triazin-2-yl)ethylamino]phenyl]sulfonyl]ethyl hydrogen sulfate, sodium salts\n451-430-4\n500717-36-2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n612-277-00-0\nreaction mass of: 4-amino-3-(4-ethenesulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{]4-chloro-6-[}4-(2-sulfonatooxyethanesulfonyl)phenylamino{]-1,3,5-triazin-2-ylamino[}-2-sulfonatophenylazo)naphthalene-2,7-disulfonate potassium/sodium;\n4-amino-5-hydroxy-6-(5-{]4-chloro-6-[}4-(2-sulfonatooxyethanesulfonyl)phenylamino{]-1,3,5-triazin-2-ylamino[}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonatooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate potassium/sodium\n451-440-9\n586372-44-3\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n612-278-00-6\nethidium bromide;\n3,8-diamino-1-ethyl-6-phenylphenantridinium bromide\n214-984-6\n1239-45-8\nMuta. 2\nAcute Tox. 2 *\nAcute Tox. 4 *\nH341\nH330\nH302\nGHS06\nGHS08\nDgr\nH341\nH330\nH302\n612-279-00-1\n(R, S)-2-amino-3,3-dimethylbutane amide\n447-860-7\n144177-62-8\nRepr. 2\nSTOT RE 2 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nH361f***\nH373**\nH319\nH315\nH317\nGHS08\nGHS07\nWng\nH361f***\nH373**\nH319\nH315\nH317\n612-280-00-7\n3-amino-9-ethyl carbazole;\n9-ethylcarbazol-3-ylamine\n205-057-7\n132-32-1\nCarc. 1B\nH350\nGHS08\nDgr\nH350\nH\n613-116-01-4\ntolylfluanid (ISO);\ndichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide;\n[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]\n211-986-9\n731-27-1\nEye Irrit. 2\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nH319\nH335\nH315\nH317\nH400\nGHS07\nGHS09\nWng\nH319\nH335\nH315\nH317\nH400\nM=10\n613-161-00-2\n2,4-diamino-6-hydroxymethylpteridinehydrobromide\n430-620-0\n76145-91-0\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Chronic 3\nH373**\nH317\nH412\nGHS08\nGHS07\nWng\nH373**\nH317\nH412\n613-162-00-8\n(6R-trans)-1-((7-ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide\n423-260-0\n100988-63-4\nMuta. 2\nSkin Sens. 1\nAquatic Chronic 2\nH341\nH317\nH411\nGHS08\nGHS07\nGHS09\nWng\nH341\nH317\nH411\n613-187-00-4\n5-(2-amino-5-cyano-6-[2-(2-hydroxyethoxy)ethylamino]-4-methylpyridin-3-ylazo)-3-methyl-2,4-dicarbonitrilethiophene\n410-530-8\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-192-00-1\n3-benzyl-exo-6-nitro-2,4-dioxo-3-aza-cis-bicyclo[3.1.0]hexane\n426-750-2\n151860-15-0\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-198-00-4\n2-amino-4-dimethylamino-6-trifluoroethoxy-1,3,5-triazine\n415-500-8\n145963-84-4\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n613-229-00-1\n1-acetyl-4-(3-dodecyl-2,5-dioxo-1-pyrrolidinyl)-2,2,6,6-tetramethylpiperidine\n411-930-5\n106917-31-1\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH315\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH315\nH317\nH410\n613-231-00-2\n2,6-diamino-3-((pyridine-3-yl)azo)pyridine\n421-430-9\n28365-08-4\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH302\nH373**\nH411\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH411\n613-232-00-8\n3-(benzo[b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazine-4-oxide\n431-030-6\n163269-30-5\nAcute Tox. 3 *\nSTOT RE 2 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH373**\nH318\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH331\nH373**\nH318\nH410\n613-234-00-9\nimidazo[1,2-b]pyridazin hydrochloride\n431-510-5\n18087-70-2\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n613-235-00-4\n2,3-dihydro-2,2-dimethyl-1H-perimidine\n424-060-6\n6364-17-6\nAcute Tox. 4*\nSTOT RE 2 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH317\nH410\n613-236-00-X\n2-chloro-3-trifluoromethylpyridine\n424-520-6\n65753-47-1\nAcute Tox. 3 *\nAcute Tox. 3 *\nSTOT RE 1\nSkin Corr. 1B\nAquatic Chronic 3\nH311\nH301\nH372**\nH314\nH412\nGHS06\nGHS05\nGHS08\nDgr\nH311\nH301\nH372**\nH314\nH412\n613-237-00-5\n6-tert-butyl-3-(3-dodecylsulfonyl)propyl-7H-1,2,4-triazolo[3.4b][1,3,4]thiadiazine\n424-950-4\n133949-92-5\nAquatic Chronic 4\nH413\n—\nH413\n613-238-00-0\nsodium 2-[[4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]sulfonyl]ethyl sulfate\n430-890-1\n81992-66-7\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\n613-239-00-6\n2-[3-(methylamino)propyl]-1H-benzimidazole\n425-760-4\n64137-52-6\nEye Dam. 1\nAquatic Chronic 3\nH318\nH412\nGHS05\nDgr\nH318\nH412\n613-241-00-7\n3-(2H-tetrazol-5-yl)pyridine\n426-810-8\n3250-74-6\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-242-00-2\nreaction products of 3,10-bis((2-aminopropyl)amino)-6,13-dichloro-4,11-triphenodioxazinedisulfonic acid with 2-amino-1,4-benzenedisulfonic acid, 2-((4-aminophenyl)sulfonyl)ethyl hydrogen sulfate and 2,4,6-trifluoro-1,3,5-triazine, sodium salts\n426-860-0\n191877-09-5\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-243-00-8\n4,4'-(1,6-hexamethylenebis(formylimino))bis(2,2,6,6-tetramethyl-1-oxylpiperidine)\n427-350-0\n182235-14-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-244-00-3\n5,7-dichloro-4-hydroxyquinoline\n427-420-0\n21873-52-9\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-245-00-9\n2-fluoro-6-trifluoromethylpyridine\n428-100-3\n94239-04-0\nFlam. Liq. 3\nAcute Tox. 4 *\nAcute Tox. 4 *\nAquatic Chronic 3\nH226\nH332\nH302\nH412\nGHS02\nGHS07\nWng\nH226\nH332\nH302\nH412\n613-246-00-4\n2-hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine\n428-200-7\n103577-66-8\nAquatic Chronic 3\nH412\n—\nH412\n613-247-00-X\n3-(2-methoxy-4-methoxycarboxybenzyl)-5-nitroindole\n428-910-7\n107786-36-7\nAquatic Chronic 4\nH413\n—\nH413\n613-248-00-5\n3,4-dimethyl-1H-pyrazole\n429-130-1\n2820-37-3\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-249-00-0\n1-(2-hydroxyethyl)-1H-pyrazol-4,5-diyldiammoniumsulfate\n429-300-3\n155601-30-2\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH318\nH317\nH411\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH411\n613-250-00-6\nreaction mass of: carbonato-bis-N-ethyl-2-isopropyl-1,3-oxazolidine;\nmethyl carbonato-N-ethyl-2-isopropyl-1,3-oxazolidine;\n2-isopropyl-N-hydroxyethyl 1,3-oxazolidine\n429-990-6\n—\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH318\nH317\nH412\n613-251-00-1\n(R)-3-[(1-methylpyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethenyl]-1H-indole\n430-560-5\n180637-89-2\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nH302\nH373**\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\n613-253-00-2\n2,2-dialkyl-4-hydroxymethyl-1,3-dioxolane;\nreaction products with ethylene oxide (alkyl is C1-12 and the sum to C13, average degree of ethoxylation is 3,5)\n430-580-4\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\nEUH019\n613-254-00-8\nforchlorfenuron (ISO);\n1-(2-chloro-4-pyridyl)-3-phenylurea\n—\n68157-60-8\nCarc. 2\nAquatic Chronic 2\nH351\nH411\nGHS08\nGHS09\nWng\nH351\nH411\n613-255-00-3\nreaction mass of isomers of: sodium [(2-hydroxyethylsulfamoyl){][}2-(2-piperazin-1-ylethylamino)ethylsulfamoyl][2-(4-aminoethylpiperazine-1-yl)ethylsulfamoyl{](sulfamoyl)[}(sulfonatophthalocyaninato)]copper(II)\n424-270-8\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-256-00-9\n3'5'-anhydro thymidine\n425-810-5\n38313-48-3\nAquatic Chronic 3\nH412\n—\nH412\n613-257-00-4\n2-phthalimidoethyl N-[4-(2-cyano-4-nitrophenylazo)phenyl]-N-methyl-β-alaninate\n426-400-9\n170222-39-6\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-258-00-X\nreaction mass of: 4-chloro-7-methylbenzotriazole sodium salt;\n4-chloro-5-methylbenzotriazole sodium salt;\n5-chloro-4-methylbenzotriazole sodium salt\n427-730-6\n202420-04-0\nSkin Corr. 1B\nAquatic Chronic 3\nH314\nH412\nGHS05\nDgr\nH314\nH412\n613-259-00-5\nreaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate;\n[2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate\n428-790-6\n72963-72-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\n613-260-00-0\n(±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolin\n430-730-9\n—\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH318\nH410\n613-261-00-6\npyrazole-1-carboxamidine monohydrochloride\n429-520-1\n4023-02-3\nAcute Tox. 4 *\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH373**\nH318\nH317\nH412\nGHS05\nGHS08\nGHS07\nDgr\nH302\nH373**\nH318\nH317\nH412\n613-262-00-1\ndisodium (E)-1,2-bis-(4-(4-methylamino-6-(4-methylcarbamoylphenylamino)-1,3,5-triazin-2-ylamino)phenyl-2-sulfonato)ethene\n427-310-2\n180850-95-7\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-263-00-7\nmonosodium 3-cyano-5-fluoro-6-hydroxypyridine-2-olate\n429-570-2\n—\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-266-00-3\n2-chloro-5-chloromethylthiazole\n429-830-5\n105827-91-6\nAcute Tox. 3 *\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH311\nH314\nH302\nH317\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH314\nH302\nH317\nH411\n613-267-00-9\nthiamethoxam (ISO);\n3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine\n428-650-4\n153719-23-4\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=10\n613-268-00-4\n(4aS-cis-)-6-benzyl-octahydropyrrolo[3.4-b]pyridine\n425-930-8\n151213-39-7\nSkin Corr. 1B\nAcute Tox. 4 *\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 2\nH314\nH332\nH302\nH373**\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH314\nH332\nH302\nH373**\nH411\n613-269-00-X\n2-thiazolidinylidenecyanamide\n427-720-1\n26364-65-8\nAcute Tox. 4*\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n613-270-00-5\n5-amino-N-(2,6-dichloro-3-methylphenyl)-1H-1,2,4-triazole-3-sulfonamide\n428-150-6\n113171-13-4\nAquatic Chronic 3\nH412\n—\nH412\n613-271-00-0\ntritosulfuron (ISO) (containing ≤ 0,02 % AMTT);\n1-[4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluoromethyl)benzenesulfonyl]urea (containing ≤ 0,02 % AMTT)\n—\n142469-14-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n613-272-00-6\npyraclostrobin (ISO);\nmethyl N-{]2-[}1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl{]phenyl[}(N-methoxy)carbamate\n—\n—\nAcute Tox. 3 *\nSkin Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH315\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH315\nH410\nM=100\n613-273-00-1\ntetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine\n427-600-9\n192439-46-6\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-274-00-7\n2,6-dichloro-1-fluoropyridiniumtetrafluoroborate\n427-400-1\n140623-89-8\nSkin Corr. 1B\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH302\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH314\nH302\nH317\nH410\n613-275-00-2\n3-(2-chloroethyl)-6,7,8,9-tetra-hydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride\n424-530-0\n93076-03-0\nAcute Tox. 3 *\nSTOT SE 2\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH301\nH371**\nH373**\nH318\nH317\nH411\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH301\nH371\nH373**\nH318\nH317\nH411\n613-276-00-8\n1-(2-chlorophenyl)-1,2-dihydro-5H-tetrazol-5-one\n426-110-2\n98377-35-6\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-277-00-3\n(4-(6-diethylamino-2-methylpyridin-3-yl)imino-4,5-dihydro-3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-one\n427-070-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n613-278-00-9\n(3-aminophenyl)pyridin-3-ylmethanone\n428-230-0\n79568-06-2\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n613-279-00-4\n2-ethyl-2,3-dihydro-2-methyl-1H-perimidine\n424-380-6\n43057-68-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH410\n613-280-00-X\ntetrahydro-1,3-dimethyl-1H-pyrimidin-2-one;\ndimethyl propyleneurea\n230-625-6\n7226-23-5\nRepr. 2\nAcute Tox. 4 *\nEye Dam. 1\nH361f***\nH302\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH361f***\nH302\nH318\n613-281-00-5\nquinoline\n202-051-6\n91-22-5\nCarc. 1B\nMuta. 2\nAcute Tox. 4 *\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nAquatic Chronic 2\nH350\nH341\nH312\nH302\nH319\nH315\nH411\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH341\nH312\nH302\nH319\nH315\nH411\n613-282-00-0\ntriticonazole (ISO);\n(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol\n—\n131983-72-7\nAquatic Chronic 2\nH411\nGHS09\nH411\n613-283-00-6\nketoconazole;\n1-[4-[4-[[(2SR, 4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone\n265-667-4\n65277-42-1\nRepr. 1B\nAcute Tox. 3 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH360F***\nH301\nH373**\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH360F***\nH301\nH373**\nH410\n613-284-00-1\nmetconazole (ISO);\n(1RS, 5RS;1RS, 5SR)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol\n—\n125116-23-6\nRepr. 2\nAcute Tox. 4 *\nAquatic Chronic 2\nH361d***\nH302\nH411\nGHS08\nGHS07\nGHS09\nWng\nH361d***\nH302\nH411\n613-285-00-7\n1-hydroxybenzotriazole, anhydrous; [1]\n1-hydroxybenzotriazole, monohydrated [2]\n219-989-7 [1]\n219-989-7 [2]\n2592-95-2 [1]\n123333-53-9 [2]\nExpl. 1.3\nH203\nGHS01\nDgr\nH203\n613-286-00-2\npotassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate;\n[containing < 0,5 % N,N-dimethylformamide (EC no 200-679-5)]\n418-260-2\n183196-57-8\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n613-286-01-X\npotassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate;\n[containing ≥ 0,5 % N,N-dimethylformamide (EC No 200-679-5)]\n418-260-2\n183196-57-8\nRepr. 1B\nSkin Sens. 1\nH360D***\nH317\nGHS08\nGHS07\nDgr\nH360D***\nH317\n613-287-00-8\n1-(3-iodo-4-aminobenzyl)-1H-1,2,4-triazole\n419-540-7\n160194-26-3\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n613-288-00-3\n1,3-bis(dimethylcarbamoyl)-imidazolium chloride\n420-930-4\n135756-61-5\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-289-00-9\n3-(4-chloro-2-fluoro-5-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole\n432-020-4\n142623-48-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-290-00-4\n4-hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3H)-one hydrochloride\n432-470-1\n189012-93-9\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n613-291-00-X\n2,4-dihydro-4-(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one\n434-820-9\n106461-41-0\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH373**\nH400\nH410\nGHS08\nGHS09\nWng\nH373**\nH410\n613-292-00-5\nN,N',N''-tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-oxo-1,3,5-triazine\n435-010-8\n26157-73-3\nMuta. 2\nAquatic Chronic 3\nH341\nH412\nGHS08\nWng\nH341\nH412\n613-293-00-0\n2-(4-tert-butylphenyl)-6-cyano-5-[bis(ethoxycarbonylmethyl)carbamoyloxy]-1H-pyrrolo[1,2-b][1,2,4] triazole-7-carboxylic acid 2,6-di-tert-butyl-4-methylcyclohexylester\n448-050-6\n444065-11-6\nAquatic Chronic 4\nH413\n—\nH413\n613-294-00-6\n2-hexyldecanoic acid [4-(6-tert-butyl-7-chloro-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester\n448-260-8\n379268-96-9\nAquatic Chronic 4\nH413\n—\nH413\n613-295-00-1\n11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c, f][1,2]thiazepine hydrochloride\n448-720-8\n363138-44-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n613-296-00-7\npentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzene-1,4-disulfonate\n418-270-7\n—\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n613-297-00-2\n5-(2-bromophenyl)-2-tert-butyl-2H-tetrazole\n420-820-6\n—\nFlam. Liq. 3\nAcute Tox. 4 *\nAquatic Chronic 2\nH226\nH302\nH411\nGHS02\nGHS07\nGHS09\nWng\nH226\nH302\nH411\n613-298-00-8\nbis-(6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(4-phenylazo)-1H-pyridin-2-one)ethylene dilactate\n421-560-6\n—\nSTOT RE 2 *\nEye Dam. 1\nAquatic Chronic 2\nH373**\nH318\nH411\nGHS05\nGHS08\nGHS09\nDgr\nH373**\nH318\nH411\n613-299-00-3\nmain component 1 (isomer 1): 2-{]6-fluoro-4-[}3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonapht-7-ylamino{]-1,3,5-triazin-2-ylamino[}-3-{]6-fluoro-4-[}3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino{]-1,3,5-triazin-2-ylamino[}-propane sodium salt;\nmain component 1 (isomer 2): 2-{]6-fluoro-4-[}3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino{]-1,3,5-triazin-2-ylamino[}-3-{]6-fluoro-4-[}3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino{]-1,3,5-triazin-2-ylamino[}-propane sodium salt;\nmain component 2: 2,3-bis-{]6-fluoro-4-[}3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino{]-1,3,5-triazin-2-ylamino[}-propane sodium salt;\nmain component 3: 2,3-bis-{]6-fluoro-4-[}3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino{]-1,3,5-triazin-2-ylamino[}-propane sodium salt\n422-610-1\n—\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-300-00-7\n1-imidazol-1-yl-octadecan-2-ol\n434-120-3\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n613-301-00-2\ndimethyl-1-{][}2-methoxy-5-(2-methyl-butoxycarbonyl)phenylcarbamoyl]-[2-octadecyl-1,1-dioxo-1,2,4-benzothiadiazin-3-yl{]methyl[} imidazole-4,5-dicarboxylate\n443-910-7\n—\nAquatic Chronic 4\nH413\n—\nH413\n613-302-00-8\ndisodium 2-(5-carbamoyl-1-ethyl-2-hydroxy-4-methyl-6-oxo-1,6-dihydro-pyridine-3-ylazo)-4-(4-fluoro-6-(4-(2-sulfonyloxy-ethylsulfonyl)-phenylamino)-1,3,5-triazine-2-ylamino)benzene sulfonate\n432-980-4\n243858-60-8\nEye Dam. 1\nH318\nGHS05\nDgr\nH318\n613-303-00-3\n2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine\n429-800-1\n95737-68-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-304-00-9\n5,6-dihydroxy-2,3-dihydro-1H-indolium bromide\n421-170-6\n138937-28-7\nAcute Tox. 4 *\nEye Dam. 1\nH302\nH318\nGHS05\nGHS07\nDgr\nH302\nH318\n613-305-00-4\n2-(2-hydroxy-4-octyloxyphenyl)-2H-benzotriazole\n448-630-9\n3147-77-1\nAquatic Chronic 4\nH413\n—\nH413\n613-306-00-X\n(2,5-dioxopyrrolidin-1-yl)-9H-fluoren-9-ylmethyl carbonate\n433-520-5\n82911-69-1\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH317\nH411\n613-307-00-5\nclothianidin (ISO);\n3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine\n—\n210880-92-5\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH410\nM=10\n613-308-00-0\n2-amino-5-methylthiazole\n423-800-5\n7305-71-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373**\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH302\nH373**\nH410\n613-309-00-6\n1-methyl-3-phenyl-1-piperazine\n431-180-2\n5271-27-2\nAcute Tox. 4 *\nAcute Tox. 4 *\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 3\nH312\nH302\nH315\nH318\nH412\nGHS05\nGHS07\nDgr\nH312\nH302\nH315\nH318\nH412\n613-310-00-1\n(-)(3S, 4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy-phenoxymethyl)-N-benzylpiperidine hydrochloride\n432-360-3\n105813-13-6\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\n613-311-00-7\nmethyl-5-nitrophenyl-guanidine\n435-500-1\n152460-07-6\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH319\nH317\nH412\nGHS07\nWng\nH302\nH319\nH317\nH412\n613-312-00-2\n2-(4-methyl-2-phenyl-1-piperazinyl)benzenemethanol monohydrochloride\n420-200-5\n—\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n613-313-00-8\n2-(4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)-1H-isoindole-1,3(2H)-dione\n442-780-9\n173838-67-0\nAquatic Chronic 3\nH412\n—\nH412\n613-314-00-3\n4-decyloxazolidin-2-one;\n4-decyl-1,3-oxazolidin-2-one\n443-770-7\n7693-82-5\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n613-315-00-9\ntetrapotassium 4-[5-[3-carboxylato-4,5-dihydro-5-oxo-1-(4-sulfonatophenyl)pyrazol-4-ylidene]-3-(piperidinocarbonyl)penta-1,3-dienylidene]-5-hydroxy-1-(4-sulfonatophenyl)pyrazole-3-carboxylate\n430-390-1\n—\nAcute Tox. 4 *\nAquatic Chronic 3\nH332\nH412\nGHS07\nWng\nH332\nH412\n613-316-00-4\ntrimethylopropane tri(3-aziridinylpropanoate);\n(TAZ)\n257-765-0\n52234-82-9\nMuta. 2\nEye Dam. 1\nSkin Sens. 1\nH341\nH318\nH317\nGHS05\nGHS08\nGHS07\nDgr\nH341\nH318\nH317\nH\n615-033-00-1\nreaction product of diphenylmethanediisocyanate, octylamine, oleylamine and cyclohexylamine (1:1.58:0.32:0097)\n430-980-9\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-034-00-7\nreaction product of diphenylmethanediisocyanate, octylamine, 4-ethoxyaniline and ethylenediamine (1:0,37:1,53:0,05)\n430-750-8\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-035-00-2\nreaction product of diphenylmethanediisocyanate, octylamine and oleylamine (molar ratio 1:1.86:0.14)\n430-930-6\n122886-55-9\nAquatic Chronic 4\nH413\n—\nH413\n615-036-00-8\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 4:1:7:1:2)\n430-940-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-037-00-3\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine and oleylamine (molar ratio 4:1:9:1)\n430-950-5\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-038-00-9\nreaction product of toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate) and aniline (molarratio 1:2)\n430-960-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-039-00-4\nreaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 3.88:1:6.38:0.47:2.91)\n430-970-4\n—\nAquatic Chronic 4\nH413\n—\nH413\n615-044-00-1\n4-chlorophenylisocyanate\n203-176-9\n104-12-1\nAcute Tox. 2 *\nAcute Tox. 4 *\nSTOT SE 3\nSkin Irrit. 2\nEye Dam. 1\nResp. Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH335\nH315\nH318\nH334\nH400\nH410\nGHS06\nGHS05\nGHS08\nGHS09\nDgr\nH330\nH302\nH335\nH315\nH318\nH334\nH410\n615-045-00-7\n4,4'-methylene bis(3-chloro-2,6-di-ethylphenylisocyanate)\n420-530-1\n—\nResp. Sens. 1\nSkin Sens. 1\nAquatic Chronic 4\nH334\nH317\nH413\nGHS08\nDgr\nH334\nH317\nH413\n616-107-00-6\ncinidon ethyl (ISO);\nethyl (Z)-2-chloro-3-[2-chloro-5-(cyclohex-1-ene-1,2-dicarboximido)phenyl]acrylate\n—\n142891-20-1\nCarc. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH317\nH410\n616-122-00-8\nmethylneodecanamide\n414-460-9\n105726-67-8\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n616-126-00-X\n1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide\n423-960-6\n139756-01-7\nAcute Tox. 4 *\nSTOT RE 2 *\nAquatic Chronic 3\nH302\nH373**\nH412\nGHS08\nGHS07\nWng\nH302\nH373**\nH412\n616-131-00-7\n1-aminocyclopentanecarboxamide\n422-950-9\n17193-28-1\nSTOT RE 1\nAcute Tox. 4 *\nEye Dam. 1\nH372**\nH302\nH318\nGHS05\nGHS08\nGHS07\nDgr\nH372**\nH302\nH318\n616-136-00-4\nreaction product of cocoalkyldiethanolamides and cocoalkylmonoglycerides and molybdenumtrioxide (1.75-2.2: 0.75-1.0:0.1-1.1)\n430-380-7\n—\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-137-00-X\n4-dichloroacetyl-1-oxa-4-azaspiro[4.5]decane\n401-130-4\n71526-07-3\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-138-00-5\nbenzoic acid, N-tert-butyl-N'-(4-chlorobenzoyl)hydrazide\n431-600-4\n112226-61-6\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-139-00-0\n(3S, 4aS, 8aS)-N-tert-butyldecahydro-3-isoquinolinecarboxamide\n420-380-5\n136465-81-1\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Chronic 3\nH302\nH318\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH412\n616-140-00-6\nN,N''-(methylenedi-4,1-phenylene)bis[N'-(4-methylphenyl)urea]\n429-380-1\n133336-92-2\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-141-00-1\nzoxamide (ISO);\n(RS)-3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-p-toluamide\n—\n156052-68-5\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM=10\n616-144-00-8\n3,4-dichloro-N-[5-chloro-4-[2-[4-dodecyloxyphenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide\n431-130-1\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-145-00-3\npethoxamide (ISO);\n2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1-enyl)acetamide\n—\n106700-29-2\nAcute Tox. 4 *\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH302\nH317\nH410\nM=100\n616-146-00-9\nN-(2-methoxy-5-octadecanoylaminophenyl)-2-(3-benzyl-2,5-dioxoimidazolidin-1-yl)-4,4-dimethyl-3-oxopentanoic acidamide\n431-330-7\n142776-95-2\nAquatic Chronic 4\nH413\n—\nH413\n616-147-00-4\n1-methyl-4-(2-methyl-2H-tetrazol-5-yl)-1H-pyrazole-5-sulfonamide\n424-160-1\n139481-22-4\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-148-00-X\nN-[6,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1H-purin-2-yl]acetamide\n424-550-1\n84245-12-5\nCarc. 1B\nMuta. 1B\nRepr. 1B\nH350\nH340\nH360FD\nGHS08\nDgr\nH350\nH340\nH360FD\n616-150-00-0\n(2R, 3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzenesulfonamide hydrochloride\n425-260-6\n—\nSTOT RE 2 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH373**\nH318\nH317\nH411\nGHS05\nGHS08\nGHS07\nGHS09\nDgr\nH373**\nH318\nH317\nH411\n616-151-00-6\nN-(2-amino-4,6-dichloropyrimidin-5-yl)formamide\n425-650-6\n171887-03-9\nAcute Tox. 4 *\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 3\nH302\nH318\nH317\nH412\nGHS05\nGHS07\nDgr\nH302\nH318\nH317\nH412\n616-152-00-1\n4-(4-fluorophenyl)-2-(2-methyl-1-oxopropyl)-4-oxo-3,N-diphenylbutanamide\n425-850-3\n125971-96-2\nAquatic Chronic 4\nH413\n—\nH413\n616-153-00-7\n4-methyl-3-oxo-N-phenyl-2-(phenylmethylene)pentanamide\n425-860-8\n125971-57-5\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-154-00-2\n3,4-dichloro-N-[5-chloro-4-[2-[4-(hexadecyloxy)phenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide\n431-110-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-155-00-8\nN,N,N',N'-tetracyclohexyl-1,3-benzenedicarboxamide\n431-040-0\n104560-40-9\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-156-00-3\n6-(2-chloro-6-cyano-4-nitrophenylazo)-4-methoxy-3-[N-(methoxycarbonylmethyl)-N-(1-methoxycarbonylethyl)amino]acetanilide\n430-500-8\n204277-61-2\nAquatic Chronic 4\nH413\n—\nH413\n616-157-00-9\n3-amino-4-hydroxy-N-(3-isopropoxypropyl)benzenesulfonamide hydrochloride\n427-780-9\n114565-70-7\nAcute Tox. 4 *\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic\nH302\nH318\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH302\nH318\nH410\n616-158-00-4\nN-[4-cyano-3-trifluoromethylphenyl]methacrylamide\n427-880-2\n90357-53-2\nSTOT RE 2 *\nAquatic Chronic 2\nH373**\nH411\nGHS08\nGHS09\nWng\nH373**\nH411\n616-160-00-5\n2,2'-azobis[N-(2-hydroxyethyl)-2-methylpropionamide]\n429-090-3\n61551-69-7\nSkin Sens. 1\nAquatic Chronic 3\nH317\nH412\nGHS07\nWng\nH317\nH412\n616-161-00-0\n2,4-dichloro-5-hydroxyacetanilide\n429-110-0\n67669-19-6\nAquatic Chronic 3\nH412\n—\nH412\n616-162-00-6\nisostearic acid monoisopropanolamide\n431-540-9\n—\nSkin Irrit. 2\nAquatic Chronic 2\nH315\nH411\nGHS07\nGHS09\nWng\nH315\nH411\n616-163-00-1\n4,4'-methylenebis[N-(4-chlorophenyl)-3-hydroxynaphthalene-2-carboxamide]\n430-350-3\n192463-88-0\nAquatic Chronic 4\nH413\n—\nH413\n616-164-00-7\ndimoxystrobin (ISO);\n(E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide\n—\n149961-52-4\nCarc. 2\nRepr. 2\nAcute Tox. 4 *\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361d***\nH332\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361d***\nH332\nH410\nM=10\n616-165-00-2\nbeflubutamid (ISO);\n(RS)-N-benzyl-2-(α, α, α, 4-tetrafluoro-m-tolyoxy)butyramide\n—\n113614-08-7\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=100\n616-166-00-8\ncyazofamid (ISO);\n4-chloro-2-cyano-N,N-dimethyl-5-p-tolylimidazole-1-sulfonamide\n—\n120116-88-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM=10\n616-167-00-3\nN,N-dibutyl-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)acetamide\n418-290-6\n168612-06-4\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n616-168-00-9\n1-dimethylcarbamoyl-4-(2-sulfonatoethyl)pyridinium\n418-440-0\n136997-71-2\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n616-169-00-4\n4-[4-(2,2-dimethyl-propanamido)]phenylazo-3-(2-chloro-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorophenyl)-2-pyrazoline-5-one\n420-220-4\n92771-56-7\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-170-00-X\n(2R)-2-amino-2-phenylacetamide\n420-370-0\n6485-67-2\nEye Irrit. 2\nSkin Sens. 1\nH319\nH317\nGHS07\nWng\nH319\nH317\n616-171-00-5\n2-(para-chlorophenyl)glycineamide\n420-830-0\n102333-75-5\nEye Dam. 1\nSkin Sens. 1\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\n616-172-00-0\nN-(2,2,6,6-tetramethyl-1-oxylpiperidin-4-yl)acetamide;\n(4-acetamido-2,2,6,6-tetramethyl-1-piperidinyl)oxidanyl\n423-840-3\n14691-89-5\nAcute Tox. 4 *\nH302\nGHS07\nWng\nH302\n616-174-00-1\n2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride\n424-560-4\n151257-01-1\nAcute Tox. 4 *\nEye Irrit. 2\nH302\nH319\nGHS07\nWng\nH302\nH319\n616-175-00-7\n2-(2-hexyldecyloxy)benzamide\n431-230-3\n202483-62-3\nAquatic Chronic 4\nH413\n—\nH413\n616-176-00-2\n3-N,N-bis(methoxyethyl)aminoacetanilide\n432-530-7\n24294-01-7\nAcute Tox. 4 *\nAquatic Chronic 3\nH302\nH412\nGHS07\nWng\nH302\nH412\n616-177-00-8\n(3-(4-(2-(butyl-(4-methylphenylsulfonyl)amino)phenylthio)-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazole-3-ylamino)-4-chlorophenyl)tetradecanamide;\nN-[3-({]4-[}(2-{]butyl[}(4-methylphenyl)sulfonyl{]amino[}phenyl)thio{]-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl[}amino)-4-chlorophenyl]tetradecanamide\n432-970-1\n217324-98-6\nAquatic Chronic 4\nH413\n—\nH413\n616-178-00-3\nN-(5-(bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)-azo)phenyl)acetamide\n434-500-9\n52583-35-4\nAquatic Chronic 4\nH413\n—\nH413\n616-179-00-9\n2-chloro-N-(4-methylphenyl)acetamide\n435-170-9\n16634-82-5\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH318\nH317\nH400\nH410\nGHS05\nGHS07\nGHS09\nDgr\nH318\nH317\nH410\n616-180-00-4\nN,N-(dimethylamino)thioacetamide hydrochloride\n435-470-1\n27366-72-9\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360D***\nH400\nH410\nGHS08\nGHS09\nDgr\nH360D***\nH410\n616-181-00-X\n4'-methyldodecane-1-sulfonanilide\n435-490-9\n17417-32-2\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-182-00-5\nN'-(1,3-dimethylbutylidene)-3-hydroxy-2-naphthohydrazide\n435-860-1\n214417-91-1\nSkin Sens. 1\nAquatic Chronic 2\nH317\nH411\nGHS07\nGHS09\nWng\nH317\nH411\n616-183-00-0\nN-dodecyl-4-methoxybenzamide\n442-340-6\n1854-15-5\nAquatic Chronic 4\nH413\n—\nH413\n616-184-00-6\n3-methyl-N-(5,8,13,14-tetrahydro-5,8,14-trioxonaphth[2,3-c]acridin-6-yl)benzamide\n442-560-2\n105043-55-8\nAquatic Chronic 4\nH413\n—\nH413\n616-186-00-7\nN,N'-(2-chloro-1,4-phenylene)bis(3-oxobutaneamide)\n443-010-4\n53641-10-4\nAquatic Chronic 3\nH412\n—\nH412\n616-188-00-8\n2-(5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylaminophenyl)pentanoic acid amide\n443-980-9\n221215-20-9\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-189-00-3\nN-[5-(bis-(2-methoxy-ethyl)-amino]-2-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-phenyl]acetamide\n444-780-4\n452962-97-9\nAquatic Chronic 4\nH413\n—\nH413\n616-190-00-9\nN-decyl-4-nitrobenzamide\n445-880-0\n64026-19-3\nAquatic Chronic 4\nH413\n—\nH413\n616-191-00-4\n2-ethyl-N-methyl-N-(3-methylphenyl)butanamide\n446-190-2\n406488-30-0\nAcute Tox. 4 *\nEye Irrit. 2\nSkin Irrit. 2\nSkin Sens. 1\nAquatic Chronic 2\nH302\nH319\nH315\nH317\nH411\nGHS07\nGHS09\nWng\nH302\nH319\nH315\nH317\nH411\n616-192-00-X\n2-[2-(3-butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5'-tert-butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2'-[(2-ethylhexyl)thio]acetanilide\n448-060-0\n727678-39-9\nAquatic Chronic 4\nH413\n—\nH413\n616-193-00-5\nN-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-5-diethylamino-phenyl]acetamide\n449-940-7\n368450-39-9\nAquatic Chronic 4\nH413\n—\nH413\n616-194-00-0\n2,2-diethoxy-N,N-dimethylacetamide\n449-950-1\n34640-92-1\nEye Irrit. 2\nH319\nGHS07\nWng\nH319\n616-196-00-1\ndisodium salt of 1-hydroxy-4-(β-(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)-N-dodecyl-2-naphthamide\n419-990-4\n—\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\n616-197-00-7\nreaction mass of: potassium N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamidate;\nN-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamide\n422-500-1\n—\nSTOT RE 2 *\nH373**\nGHS08\nWng\nH373**\n616-198-00-2\n1,3-bis[12-hydroxy-octadecamide-N-methylene]-benzene\n423-300-7\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-200-00-1\nreaction mass of: N,N'-ethane-1,2-diylbis(hexanamide);\n12-hydroxy-N-[2-[(1-oxyhexyl)amino]ethyl]octadecanamide;\nN,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide)\n432-430-3\n—\nSkin Sens. 1\nAquatic Chronic 4\nH317\nH413\nGHS07\nWng\nH317\nH413\n616-201-00-7\n12-hydroxyoctadecanoic acid, reaction products with 1,3-benzenedimethanamine and hexamethylenediamine\n432-840-2\n220926-97-6\nAcute Tox. 4 *\nAquatic Chronic 4\nH332\nH413\nGHS07\nWng\nH332\nH413\n616-202-00-2\nreaction mass of: 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide;\n2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide;\n2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide\n434-330-5\n—\nCarc. 2\nSkin Sens. 1\nAquatic Chronic 4\nH351\nH317\nH413\nGHS08\nGHS07\nWng\nH351\nH317\nH413\n616-203-00-8\nreaction mass of: N-[5-[bis-(2-methoxyethyl)amino]-2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl-azo)phenyl]acetamide;\nN-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)5-diethylaminophenyl]acetamide\n442-280-0\n—\nAquatic Chronic 4\nH413\n—\nH413\n616-204-00-3\nN,N''-(methylenedi-4,1-phenylene)bis[N'-octylurea]\n451-060-3\n122886-55-9\nAquatic Chronic 4\nH413\n—\nH413\n617-021-00-1\nmethylethylketone peroxide trimer\n429-320-2\n—\nOrg. Perox. B****\nAsp. Tox. 1\nSkin Irrit. 2\nSkin Sens. 1\nH241\nH304\nH315\nH317\nGHS01\nGHS02\nGHS08\nGHS07\nDgr\nH241\nH304\nH315\nH317\n617-022-00-7\nreaction mass of: 1,2-dimethylpropylidene dihydroperoxide;\ndimethyl 1,2-benzenedicarboxylate\n442-480-8\n—\nOrg. Perox. C\nAcute Tox. 4 *\nSkin Corr. 1B\nSkin Sens. 1\nAquatic Chronic 2\nH242\nH302\nH314\nH317\nH411\nGHS02\nGHS05\nGHS07\nGHS09\nDgr\nH242\nH302\nH314\nH317\nH411\n647-017-00-5\nlaccase\n420-150-4\n80498-15-3\nResp. Sens. 1\nH334\nGHS08\nDgr\nH334",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2009/790/annex/II",
    "retrieved_at": "2026-11-01T14:51:18.600132+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}